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Thesis Abstract 
 
This thesis examines the relationship between checkpoint adaptation and 
micronuclei in human cancer cells with damaged DNA. When cancer cells are exposed to 
genotoxic agents they can form micronuclei, although the precise process has yet to be 
described. I examined glioma cells (M059K) and found that 48% of the cells contain 
micronuclei after treatment with cisplatin.  Treated cells also underwent checkpoint 
adaptation: they signalled damaged DNA, had active Chk1, arrested in G2-phase, and 
then entered mitosis. The relationship between checkpoint adaptation and micronuclei 
was confirmed by use of chemical inhibitors against Chk1 or Cdk1, which have key roles 
in checkpoint adaptation. When Chk1 was inhibited in treated cells, additional 
micronuclei formed, whereas if Cdk1 was inhibited, no additional micronuclei formed. I 
treated normal cells (WI-38) with cisplatin and found that they did not undergo 
checkpoint adaptation or form micronuclei. These data demonstrate that micronuclei are 
an outcome of checkpoint adaptation. 
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Chapter 1 - Literature review 
 This thesis is about the relationship between damaged DNA, checkpoint 
adaptation, and micronuclei formation in brain cancer (glioma) cells. Here I provide a 
review on these processes and how they contribute to genomic change in glioma cells. 
 I hypothesize that micronuclei form from cells that undergo checkpoint 
adaptation, a process in which cells enter mitosis with damaged DNA. Secondly, I 
hypothesize that micronuclei continue to damage their DNA as a result of aberrant DNA 
replication. 
 
1.1. The cell cycle 
 The cell cycle is composed of four distinct phases: gap-1 (G1), synthesis (S), gap-
2 (G2), collectively known as interphase, and M-phase (mitosis and cytokinesis) [1]. In 
G1-phase, cells nearly double in size and synthesize proteins and mRNAs required for S-
phase. Importantly, human cells in G1-phase contain 2n DNA, which corresponds to 23 
chromosome pairs. When the cell enters S-phase the DNA is duplicated by a process of a 
semi-conservative replication. When DNA replication is completed the cell enters G2-
phase with 4n DNA. Although the DNA content has doubled, the replicated 
chromosomes remain connected by the centromere and are defined as sister chromatids 
until they are separated in mitosis. In G2-phase cells continue to grow and synthesize 
additional proteins and mRNAs that are required for M-phase. 
The final phase of the cell cycle is M-phase, which corresponds to both mitosis 
(separation of chromosomes) and cytokinesis (division of cytoplasm). Mitosis is 
subdivided into five stages: prophase, prometaphase, metaphase, anaphase, and telophase. 
2 
 
Prophase and prometaphase represent the earliest stages of mitosis. They are 
characterized by the condensation of sister chomatids and disassembly of the nuclear 
envelope. Condensation occurs after chromatin modifications, which include the 
phosphorylation of histone H3 on serine 10 [2]. After condensation, the sister chromatids 
become attached to the mitotic spindle, a structure composed of an array of microtubules. 
In metaphase, the sister chromatids are aligned at the equatorial plate with the aid of a 
spindle apparatus that originates at each pole. In anaphase, the spindle apparatus 
separates the sister chromatids by pulling the chromosomes towards the poles. The 
chromosomes decondense during telophase, while the nuclear envelope reforms to 
produce two distinct daughter nuclei. As telophase is occurring, cytokinesis divides the 
cytoplasm, which contains the nuclei and other organelles equally into two daughter cells.  
Understanding the changes that occur in cells during mitosis allows us to 
distinguish mitotic cells from those in interphase. For example, condensed chromosomes 
and the phosphorylation of histone H3 on serine 10 can be used to confirm mitosis [2]. In 
addition, the shape of a cell can be used to distinguish mitosis. Cells in interphase are flat, 
but during mitosis they become rounded [3]. The round shape is caused by changes in the 
polymerization of actin filaments, which are a structural network of proteins in the 
cytoplasm [4]. 
 
1.2. Regulation of the cell cycle 
 The cell cycle is controlled by a family of threonine/serine kinases known as 
cyclin dependent kinases (Cdks) [5]. As their name suggests, they are dependent on the 
presence of cyclin regulatory subunits. There are four classes of Cdks involved in the cell 
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cycle: G1/S-Cdks, S-Cdks, G2-Cdks, and M-Cdks. Collectively, G1/S-Cdks, S-Cdks, and 
G2-Cdks manage the transitions between phases in interphase, whereas M-Cdks regulate 
mitosis. 
 Cdk1 is the M-Cdk that is required for mitosis [5]. It is highly regulated and must 
undergo three activation steps before mitosis can begin. First, Cdk1 must bind to its 
regulatory subunit cyclin B1. The amount of cyclin B1, unlike Cdk1, oscillates 
throughout the cell cycle. Cyclin B1 is absent during most of interphase; its levels 
increase in late G2-phase until a peak is reached in mitosis. However, cyclin B1 is rapidly 
degraded by the proteasome complex during anaphase.  
 The second activation step of the Cdk1/cyclin B1 complex is a conformational 
change to allow adenosine triphosphate (ATP) to enter the catalytic site [6]. This occurs 
after Cdk1 has been phosphorylated on threonine 161 by the Cdk-activating kinase 
(CAK). This activation step is held in check by the presence of inhibitory phosphates on 
amino acids (threonine 14 and tyrosine 15), which maintain Cdk1 in an inactive state [6]. 
These inhibitory phosphates are added by the protein kinases Wee1 and Myt1 in G2-
phase [5, 6]. In the final activation step, the protein phosphatase cell division cycle 25C 
(Cdc25c) removes the phosphates on threonine 14 and tyrosine 15 from the Cdk1/cyclin 
B1 complex.  
 Dysregulation of the Cdk1 activation steps can lead to uncontrolled cellular 
proliferation. For example, induced overexpression of cyclin B1 in esophageal squamous 
carcinoma cells (ESCC) [7] and overexpression of Cdc25 in osteosarcoma cells (U2OS) 
[6] has been reported to accelerate the G2/M-phase transition. In these cells, Cdk1 
remains active regardless of the presence of Wee1. In addition to the overexpression of 
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these proteins, ectopic expression of cyclin B1 during G1-phase or S-phase has been 
reported to trigger cell death by apoptosis [8]. Therefore controlling the Cdk1 activation 
steps is crucial to preventing premature mitosis. Furthermore, these steps provide a 
control mechanism to prevent cells with damaged DNA from entering mitosis, a point 
that will be discussed later in my thesis.  
 Cdk1 phospho-activity can also be used as a method for detecting mitosis. 
Cdk1/cyclin B1 phosphorylates at least 75 different proteins [5]. For example, 
Cdk1/cyclin B1 phosphorylates protein phosphatase 1 (PP1Cα) on threonine 320 [9]. 
With this information, I developed an assay to measure Cdk1 protein kinase activity in 
human cancer cells. I found that the phosphorylation levels of PP1Cα in mitotic colon 
carcinoma cells (HT-29) are approximately ten times higher than in interphase cells [10]. 
Therefore the presence of phospho-Thr320-PP1Cα can also be used to confirm mitosis.   
 
1.3. Cdk1 inhibitors 
 Because Cdk1 activity is required for mitosis, it has become an attractive 
therapeutic target for anticancer drugs. Since 1993, over 140 Cdk inhibitors have been 
developed [11, 12]. One of these inhibitors is the small molecule CR8 [12, 13]. CR8 is an 
analogue of roscovitine, which is currently undergoing phase II clinical trials for non-
small cell lung carcinoma (NSCLC) [12]. CR8 and roscovitine are 2,6,9-trisubstituted 
purine and are ATP competitors that bind to the active site of Cdk1. This binding blocks 
the phospho-activity of Cdk1. HT-29 cells treated with 10 µM CR8 do not enter mitosis 
as confirmed by the absence of phospho-Thr320-PP1Cα and the absence of cell rounding 
[3]. Using the Cdk1 assay I developed, I was able to confirm that treatment with 10 µM 
5 
 
CR8 reduces the levels of phospho-Thr320-PP1Cα by approximately 60% [10]. By 
contrast, an inactive methylated form of CR8 does not prevent cell rounding or the 
phosphorylation of PP1Cα [3]. These studies confirm that treatment with CR8 can be 
used as a reliable method to block mitosis in human cells.   
  
1.4. Cell-cycle checkpoints 
 In addition to the regulation by Cdks, the cell cycle is also controlled by a set of 
biochemical pathways called cell-cycle checkpoints. They prevent entry into the next 
phase of the cell-cycle when the preceding phase has not been completed. Importantly, 
cell-cycle checkpoints also prevent cell cycle progression if DNA is either damaged or 
incorrectly organized [14]. Cells have one M-phase checkpoint, the spindle assembly 
checkpoint (SAC) [15], and two interphase checkpoints, which are both referred to as 
DNA damage checkpoints [16].   
 The SAC is active during mitosis and leads to a cell-cycle arrest in metaphase. Its 
role is to ensure that chromosomes are accurately distributed to daughter cells. To 
accomplish this, chromosomes must attach to microtubules such that each sister 
kinetochore is attached to opposite poles of the bipolar spindle apparatus (amphitelic 
attachment). Then the chromosome must align along the equatorial plate, which requires 
equal tension between kinetochore microtubules. If these conditions are not met, cells 
arrest in metaphase. However, if the spindle structure and chromosome alignment can be 
re-established, the checkpoint is ended and cells will progress into anaphase. 
 In contrast to the SAC, the DNA damage checkpoints monitor the transition 
between G1/S-phase and G2/M-phase [16]. DNA damage checkpoints protect cells from 
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transmitting genomic changes to daughter cells by ensuring that damaged DNA is 
repaired before entry into the next phase of the cell cycle. Importantly, most cancer cells 
contain a defective G1/S DNA damage checkpoint due to mutations in the p53 pathway 
[17, 18], misregulation of the G1/S-Cdks or their respective cyclins [18], or mutations to 
the retinoblastoma (Rb) gene [18, 19].  As a result, cancer cells with damaged DNA are 
more likely to accumulate in G2-phase than in the G1-phase of the cell cycle.  
 
1.5. G2/M DNA damage checkpoint 
 In this thesis, I will be examining cells that arrest in G2-phase at the DNA damage 
checkpoint prior to entering mitosis with damaged DNA. To understand how this occurs, 
a comprehensive understanding of the G2/M DNA damage checkpoint is required. 
 The G2/M DNA damage checkpoint is comprised of sensors, transducers, and 
effector molecules [20]. Together, these molecules initiate a phosphorylation cascade that 
causes a cell-cycle arrest in G2-phase. The two enzymes that are responsible for the 
phosphorylation cascade are ataxia-telangiectasia mutated (ATM) and ATM Rad3-related 
(ATR) [14]. ATM and ATR are signal transducer molecules and belong to the 
phosphoinositide 3-kinase-related kinase (PIKK) super family. Although both ATM and 
ATR checkpoint pathways can be activated at the same time, each responds to a different 
type of damaged DNA; ATR responses to single-strand breaks (SSB), while ATM 
responds to double-strand breaks (DSB). 
 In the presence of SSB, DNA becomes coated by replication protein A (RPA) 
[14]. RPA binds to and stabilizes single-stranded DNA (ssDNA). When the RPA-ssDNA 
complex is formed it becomes a binding site for ATR interacting protein (ATRIP). 
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ATRIP is a sensor molecule that participates with the RPA-ssDNA complex to recruit 
inactive ATR homodimers to sites of damaged DNA. Once ATR binds with ATRIP, 
ATR undergoes autophosphorylation, which causes it to separate into two active 
monomer units. In contrast to SSB, DSB are detected by Mer11-Rad50-Nbs1 (MRN) 
complex [16], which recruits ATM to sites of damaged DNA. Like ATR, ATM exists as 
an inactive homodimer until it is activated by the MRN complex. Once ATM becomes 
active, repair complexes convert DSB to SSB, which subsequently activates ATR [14]. 
Together, ATM and ATR have been reported to phosphorylate approximately 700 
different protein substrates on 900 different sites [21]. These substrates have important 
roles in signalling DNA damage repair and checkpoint activation. 
 In the presence of either SSB or DSB, ATM and ATR phosphorylate the histone 
variant H2AX on serine 139 [22], which then becomes γH2AX. Paull et al. reported that 
histone γH2AX foci typically appear one to three minutes after a DNA break is 
introduced [23]. Histone γH2AX is involved in recruiting repair proteins, such as breast 
cancer 1 (Brca1), to damaged sites [23] and stimulating chromatin relaxation [24]. If 
damaged DNA is successfully repaired, histone γH2AX is subsequently 
dephosphorylated by protein phosphatase 1 (PP1) [25] and protein phosphatase 2 (PP2) 
[26]. The detection of histone γH2AX is a reliable marker for damaged DNA in cells 
because it is present immediately after the introduction of DNA damage and is 
dephosphorylated when damaged DNA is repaired.  
 In addition to signalling for DNA damage repair, ATM and ATR also trigger 
checkpoint activation (Figure 1). In normal cells, ATM and ATR have two main 
checkpoint pathways that can arrest cells in interphase: the p53-p21 dependent pathway 
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and the checkpoint kinase (Chk) dependent pathway. The p53-p21 dependent pathway 
initiates the G1/S DNA damage checkpoint. This requires activation of the tumour 
suppressor protein p53 by ATM and ATR. In addition to initiating the DNA damage 
checkpoint, p53 triggers cell death through apoptosis, and repair of DSB [17, 27-29]. In 
the absence of damaged DNA, p53 activity is inhibited by the binding of 
minichromosome maintenance 2 (Mcm2) [30]. Mcm2 is an E3 ubiqiutin ligase that 
mediates the degradation of p53 by the ubiquitin-proteasome pathway. ATM and ATR 
phosphorylate p53 on threonine 15 and serine 20, which inhibits the binding of Mcm2. 
This allows p53 to be imported into the nucleus where it acts as a transcription factor for 
several genes, including one that encodes the Cdk inhibitor p21. Once synthesized, p21 
binds to G1/S-Cdks and S-Cdks (Cdk4/6/cyclin D [31]
 and Cdk2/cyclinA/E [32]). This 
binding initiates a cell-cycle arrest in either G1-phase or S-phase. 
 In at least 80% of cancer cells, the p53-p21 pathway is non-functional [17]. In 
these cells, damaged DNA in G1-phase and S-phase might not initiate a cell-cycle arrest. 
Instead, in the presence of damaged DNA, the checkpoint kinase dependent pathway is 
required to arrest cells in G2-phase. In this pathway, ATM and ATR phosphorylate 
effector molecules checkpoint kinase 1 (Chk1) on serine 317 and serine 345 [33] and 
checkpoint kinase 2 (Chk2) on threonine 26, threonine 68, and serine 50, respectively 
[34]. These phosphates are required for Chk1 and Chk2 activation and are only present if 
DNA is damaged. Chk1 and Chk2 inhibit entry into mitosis by two mechanisms: down-
regulating the activity of Cdc25C and increasing the activity of Wee1. As shown in 
Figure 1, Chk1 and Chk2 participate in cell-cycle regulation by interacting with Cdc25 
and Wee1. Chk1 and Chk2 phosphorylate Cdc25C on serine 216 [35], which causes 
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Cdc25C to bind with a protein complex named 14-3-3. This causes Cdc25C to be 
sequestered in the cytoplasm where it will eventually be degraded by the proteasome 
complex. Simultaneously, Chk1 phosphorylates Wee1 on serine 642 so that it remains 
active [36].  
 Although both Chk1 and Chk2 can be activated in response to damaged DNA, 
active Chk1 (but not Chk2) is crucial to maintaining the G2-phase arrest. Chen et al. 
reported that down-regulation of Chk1 by RNA interference was sufficient to abrogate 
the G2/M DNA damage checkpoint in human lung cancer cells (H1299) treated with the 
genotoxic agent doxorubicin [37]. In a subsequent study, Carrassa et al. reported that 
down-regulation of Chk1 also eliminated the G2/M DNA damage checkpoint in up to 
50% of human colon carcinoma cells (HCT-116) exposed to ionizing radiation or cis-
diamminedichloroplatinum (cisplatin) [38]. In the same study it was reported that 
knockdown only of Chk2 by RNA interference did not have an effect on the G2/M DNA 
damage checkpoint in these cells.  In recent complementary experiments, Bo et al. 
reported that overexpression of Chk1 (but not Chk2) in human gastric cancer cells 
(BGC823) treated with diallyl disulfide increased the number of cells in G2-phase [39]. 
They also showed that knockdown of Chk1 (but not Chk2) with siRNAs specific to Chk1 
partially prevented the down-regulation of Cdc25C and Cdk1/cyclin B1 activity. 
Together these reports suggest that Chk1 is more important than Chk2 in maintaining the 
G2-phase in arrest in the presence of damaged DNA. Therefore, for this thesis the 
phosphorylation of Chk1 on serine 317 and serine 345 will be used as a marker to detect 
the activation of the DNA damage checkpoint. 
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1.6. Chk1 inhibitors  
 Recently, there has been an interest in developing compounds that inhibit Chk1 or 
other proteins required to maintain the DNA damage checkpoint. Chk1 inhibitors prevent 
cell-cycle arrest due to damaged DNA and promote mitotic cell death. Experimentally, 
the DNA damage checkpoints can be inhibited with high concentrations of caffeine. 
Caffeine inhibits ATM and ATR, however, the concentration of caffeine required to 
abrogate the DNA damage checkpoints in humans is not clinically attainable [40]. As 
such, small molecules with a higher specificity for a protein kinase, such as Chk1, have 
been developed. 
 An example of a commonly used Chk1 inhibitor is the indolocarbazole UCN-01 
(7-hydroxystraurosporine). It is an ATP competitor that is approximately 100,000 times 
more potent than caffeine [40]. Busby et al. reported that UCN-01 treatment prevented 
Chk1 from phosphorylating Cdc25C on serine 216 in erythroblast leukemia cells (K562) 
after treatment with 8 Gy (Gray) of ionizing radiation [41].  Cells did not arrest in G2-
phase and instead entered mitosis. However, clinical studies have reported that UCN-01 
has a high affinity for human plasma protein (α1-acid glycoprotein), which extends its 
half-life and limits its bioavailability [40, 42]. Cell culture studies have confirmed that 
cells incubated with human serum instead of bovine serum, which is more commonly 
used in laboratories, required 100 times more UCN-01 to abrogate the DNA damage 
checkpoint [40]. Therefore other Chk1 inhibitors have been developed to avoid these 
undesirable features. 
 A promising alternative to UCN-01 is the indolocarbazole derived molecule, 
Gö6976. Gö6976 is another ATP competitor molecule that binds to the active site of 
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Chk1 and Chk2, but not α1-acid glycoprotein. In addition, Gö6976 has been reported to 
have a higher specificity for Chk1 compared to UCN-01 [43]. Kohn et al. reported that 
30 nM to 100 nM Gö6976 abrogated the S-phase and G2-phase arrest induced by SN-38 
(the active component of the topoisomerase I inhibitor irinotecan) in human breast 
carcinoma cells (MDA-MB-231) [40]. As reported with UCN-01, Gö6976 prevents Chk1 
from inhibiting Cdc25C [40, 43], which then allows cells to enter mitosis. Due to its high 
specificity for Chk1, and its low affinity for α1-acid glycoprotein [40], Gö6976 treatment 
can be used as a reliable method to study the effects of abrogating the DNA damage 
checkpoints in human cells. 
 
 1.7. DNA damaging agents 
 If damaged DNA is so severe that it cannot be repaired during the cell-cycle 
arrest, cell death will occur [16]. This is the basis of genotoxic anticancer treatments. To 
date, ionizing radiation is the most frequently used anticancer treatment [44]. 
Approximately 50% of all cancer patients are treated with ionizing radiation; however, 
many genotoxic chemical agents, which also damage the DNA, have been developed to 
treat cancer patients [45]. In the experiments described in this thesis, I have selected three 
genotoxic agents as examples of anticancer drugs: camptothecin (CPT), S23906-1, and 
cisplatin (Table 1). Notably, each genotoxic agent has a different mechanism of action.  
CPT is a quinoline alkaloid that was first isolated from Camptotheca acuminata 
bark extracts in 1966 while screening for natural anticancer compounds [46]. Since its 
discovery, two CPT analogues (topotecan and irinotecan) have been approved as 
chemotherapic agents to treat ovarian, cervical, colorectal, brain, and small cell lung 
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cancers [46, 47]. CPT and its analogues inhibit topoisomerase I (Topo I). Topo I is an 
enzyme that relieves torsional strain in DNA by removing supercoils during DNA 
replication and transcription. Topo I introduces single-stranded nicks along the 
phosphodiester backbone of the DNA, passing the uncleaved strand through this nick, 
and then religating the relaxed DNA [46]. When CPT is present, it forms hydrogen bonds 
between aspartate 533 and arginine 364 on Topo I, and the amine on cytosine, after the 
DNA nick has been introduced [48]. These hydrogen bonds stabilize the binding of Topo 
I to the 3' end of the DNA and prevent religation. Eventually, when the replication fork 
collides with the CPT-Topo I-DNA complex, the SSB induced by Topo I is converted 
into a DSB [46, 48].  
  Like topotecan and irinotecan, S23906-1 is an analogue of a natural product 
isolated from a plant extract. It was synthesized from its parent molecule acronycine, 
which was extracted from Sarcomelicope simplicifolia [49]. S23906-1 has been tested in 
clinical studies and has been shown to exhibit anticancer activity towards multiple 
myeloma [50] as well as several solid tumours. S23906-1 is an atypical alkylating agent 
that covalently binds to the N2 of guanine in the minor groove of DNA [51, 52]. It also 
has a unique ability to promote DNA strand separation.  Interestingly, the effects of 
S23906-1 are only detected when DNA replication begins. Léonce et al. reported that 
S23906-1 induced DSB during S-phase, and that treatment with the DNA polymerase α 
inhibitor aphidicolin prevents this damage [51]. In 2010, Cahuzac et al. reported that 
treatment with S23906-1 induced cell death by mitotic catastrophe [52]. 
 In contrast to CPT and S23906-1, cisplatin is an inorganic molecule, based on 
platinum. It was first synthesized in 1845 [53], but was not discovered to have anticancer 
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properties until the 1960s [54]. Rosenberg et al. first reported that cisplatin treatment 
inhibited cell division in Escherichia coli [55] and then later reported that cisplatin 
injections also caused tumour regression in mice harboring transplanted sarcomas [56]. 
Cisplatin was subsequently approved as an anticancer drug for humans in 1978 [53]. 
Currently, cisplatin is used to treat testicular, lung, ovarian, and head and neck cancers 
[53]. It is also used in combination with other drugs such as temozolomide (TMZ) to treat 
brain cancers [57, 58]. Cisplatin induces intra-strand, inter-strand, and DNA-protein 
crosslinks [53, 59]. The chlorine atoms of cisplatin are replaced with the N7 of either 
guanine or adenine. Cisplatin binds more tightly to nitrogen, because nitrogen balances 
the platinum charge more effectively than chlorine. Eastman reported that 90% of DNA 
crosslinks induced by cisplatin occur between two adjacent guanines (1,2-GpG) [60]. 
When the crosslinks are encountered by either the DNA replication or transcription 
machinery, they are subsequently converted into either SSB or DSB following collision 
[53].   
 
1.8. Micronuclei  
 A common outcome of treating cells with genotoxic agents including cisplatin 
and CPT is formation of micronuclei. Micronuclei can form in cells with damaged DNA 
that enter mitosis. As such, it has been suggested that micronuclei formation may require 
checkpoint adaptation, a process that will be discussed later in this thesis. Here I provide 
a detailed review of micronuclei and their relation to mitosis, damaged DNA, and 
genomic change in cells.  
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1.8.1. Micronuclei and their relationship to mitosis   
 Micronuclei form from whole chromosomes [61, 62] or chromosome fragments 
[63] that do not attach properly to the spindle apparatus, and fail to be incorporated into 
daughter nuclei after completion of telophase. Eventually, the excluded chromosome or 
chromosome fragments are encased by smaller nuclei that function independently of the 
main nucleus.  
 There are four related mechanisms that are known to disrupt the attachment of 
chromosomes or chromosome fragments to the spindle apparatus: (1) unrepaired (or 
incorrectly repaired) DNA breaks [64, 65], (2) dysfunctional mitotic spindle complexes 
or microtubules [66-68], (3) defects in kinetochore proteins or assembly [69-71], and (4) 
a defective mitotic checkpoint [71]. Although genotoxic treatment may cause micronuclei 
to form as a result of all four of these mechanisms, unrepaired DNA breaks are expected 
to be the biggest contributor.  
 
1.8.2. Micronuclei arise from unrepaired DNA breaks  
 Damaged DNA can interfere with the attachment of a chromosome to the spindle 
apparatus, if the centromere is missing or damaged (Figure 2). This is because 
centromeric DNA provides the binding site for the kinetochore proteins, which are 
required to connect the chromosomes to the spindle microtubules. Acentric (centromere 
lacking) chromosome fragments, which are generated through ionizing radiation and/or 
genotoxic chemical agents, are known to cause the formation of micronuclei. Cornforth 
and Goodwin reported that up to 84% of micronuclei that form in skin fibroblasts 
obtained from live donors and then treated with 6 Gy of ionizing radiation, contained 
chromosome fragments that lacked centromeric DNA [72]. In another study, Jirsova et al. 
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reported that skin fibroblasts treated with 2-80 µM cisplatin gave rise to micronuclei 
containing acentric chromosome fragments [64]. Utani et al. reported that high 
concentrations of CPT (14 µM) also induced chromosome fragmentation and micronuclei 
formation in human colon carcinoma cells (COLO 320DM) [73]. 
 In cases where a centromere is damaged, missegregation of whole chromosomes 
may also occur. Guerrero et al. reported that localized damage to the centromeric DNA of 
mouse embryonic fibroblasts (Dido MEF) led to the generation of merotelic chromosome 
attachments (kinetochores that are attached to both spindles) and resulted in 2.6 times 
more micronucleated cells than those without damaged centromeres [74]. It has been 
suggested that damage to centromeric DNA in human cells disrupts the binding of the 
histone H3 variants CENPA and CENPB, which are required for kinetochore assembly 
[71]. 
 In some cases, DNA damage can lead to the generation of dicentric (two 
centromeres) chromosomes (Figure 2) [71, 75, 76]. Typically, this occurs when the 
telomere regions of two chromosomes, which are either damaged or eroded, fuse. When 
anaphase begins, the centromeres of the dicentric chromosome are pulled to opposite 
poles. This process stretches the chromosome and forms what is known as a 
nucleoplasmic bridge (NPB) between the daughter nuclei. Eventually, the NPB breaks in 
cytokinesis and the broken DNA fragments are enclosed in micronuclei. Pampalona et al. 
reported that chromosome fusions arise in primary epithelial cells (HMEC) that have 
damaged telomere ends [77]. In this study, the researchers observed that NPB formed 
between daughter nuclei after the spindle apparatus failed to separate a dicentric 
chromosome. Approximately 40% of micronuclei examined later harboured dicentric 
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chromosome fragments. In another study, Thomas et al. reported that lymphoblasts 
(WIL2- NS) treated with 2 Gy of radiation were 25 times more likely to form NPB 
containing dicentric chromosomes than non-treated cells [76]. 
 
1.8.3. Micronuclei induce aneuploidy 
 Micronuclei can arise from cells with damaged DNA that enter mitosis, but they 
also can induce further genomic changes once present. The most common type of 
genomic change reported in micronucleated cells that undergo mitosis is whole 
chromosome aneuploidy. This can occur if the chromosomes in micronuclei are not 
replicated, actively degraded, or exported out of the cell. Okamoto et al. reported that 
human colon carcinoma (CCL 220) and cervical carcinoma (HeLa) cells harbouring 
micronuclei that lack nuclear lamina do not replicate DNA and give rise to daughter cells 
with a different chromosome number [78]. After analysis by the terminal dUTP nick-end 
labelling (TUNEL) assay, Terradas et al. reported that chromosomes are degraded by an 
apoptotic-like pathway [63]. In some cases micronuclei undergo nuclear-envelope 
collapse due to either absent or discontinuous lamina [79]. Hatch et al. reported that 60% 
of micronuclei lacking lamin B1 in U2OS cells ruptured and degraded DNA prior to 
mitosis [79]. Similar observations were made using cervical (HeLa), breast (MDA-MB-
231), and prostate (DU 145) cancer cells in this study. 
 
1.8.4. Micronuclei induce break-fusion-bridge cycle   
 In addition to causing chromosome aneuploidy, micronuclei containing 
chromosomes that lack telomeres can initiate a break-fusion-bridge (BFB) cycle [71, 80]. 
17 
 
BFB cycles occur when a chromosome lacking telomeres is replicated into two sister 
chromatids, which also lack telomeres [71]. The two sister chromatids then fuse, creating 
a dicentric chromosome. During anaphase the dicentric chromosome is broken, but at a 
site different from that of the original fusion. The daughter cells receive unequal 
chromatid fragments, which again lack telomeres. As a result of the absent telomeres, the 
BFB cycle continues. Notably, during the BFB cycle some genes can be amplified 
whereas others are lost depending on the location of the chromosome break. This 
mechanism has been observed in Chinese hamster fibroblasts (GMA32) whereby a BFB 
cycle lead to the amplification of several genes on chromosome 1 as detected by 
fluorescence in situ hybridization (FISH) [80].  
 
1.8.5. Protein recruitment is impaired in micronuclei 
 Although micronuclei appear to be morphologically similar to the main nucleus, 
several studies have reported that micronuclei are impaired in the recruitment of proteins 
involved in transcription, DNA replication, and DNA repair. Reduced protein recruitment 
in micronuclei denotes that DNA sequences will be less efficiently transcribed, 
replicated, and repaired, which will alter biological processes in the cell.   
 As a result of impaired protein recruitment, most micronuclei are transcriptionally 
inactive. Hoffelder et al. reported that 96% of micronuclei in oral squamous-cell 
carcinoma cells (SCC) did not incorporate fluorescently labelled UTP (uridine 
triphosphate), which is used to measure transcriptional activity, despite high levels of 
UTP in the main nucleus [81]. In this study, only 13% of micronuclei contained the RNA 
Polymerase II holoenzyme, which is required for the elongation phase of transcription. 
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Thus even though the DNA sequences may be present, it is as if the genes are lost since 
they cannot be expressed in most micronucleated cells. 
 In addition to impaired transcriptional activity, DNA replication is also reported 
to be less efficient in micronuclei [61, 63]. Crasta et al. reported that at least 20% of 
micronuclei in RPE-1 cells do not begin DNA replication until late G2-phase [61]. This 
delay in DNA replication was associated with a significant reduction in the helicase 
components, Mcm2 and Mcm3, as well as chromosome licensing and DNA replication 
factor 1 (Cdt1). If DNA inside a micronucleus is not replicated before mitosis, it is 
impossible to pass on genomic information to both daughter cells. Therefore impaired 
DNA replication in micronucleated cells will enhance chromosome aneuploidy [61, 63]. 
 Damaged DNA inside a micronucleus is also not efficiently repaired. 
Interestingly, in the presence of damaged DNA, micronuclei are able to recruit ATR, 
ATM, and histone γH2AX [61, 63], but other downstream constituents involved in the 
DNA damage response such as 53PB1 [61, 63, 82, 83], Rad50 [61, 82], Brca1 [61] and 
Mer11 [63] are not efficiently recruited. Importantly, both transcription and DNA 
replication have been reported to induce DNA breaks [61]. Therefore micronuclei can 
continuously damage their own DNA in the absence of a genotoxic agent. Consequently, 
unrepaired DNA breaks increase the number of chromosomal rearrangements, gene 
deletions, and nucleotide polymorphisms.  
 
1.8.6. Micronuclei have fewer nuclear pore complexes 
 The reduced recruitment of proteins involved in transcription, DNA replication, 
and repair is thought to be due to defective nucleo-cytoplasmic transport. Micronuclei are 
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reported to have a reduced density of nuclear pores compared to the main nucleus [61, 
63, 81]; however the reason for the reduction in nuclear pores density is not known. 
Nuclear pores are large protein complexes that span the nuclear envelope and allow the 
passage of large proteins with nuclear import signals into the nucleus. Since there are 
fewer nuclear pores in a micronucleus the recruitment of proteins is thought to be much 
slower compared to that in the main nucleus. Hoffelder et al. measured nuclear uptake 
using exogenous glucocorticoid-GFP and reported that only 10% of micronuclei were 
able to import this protein at a detectable level [81]. In another study, Crasta et al. 
reported that nuclear import in a micronucleus was on average 25% less efficient 
compared to that of the main nucleus [61]. 
 
1.8.7. Micronuclei induce chromothripsis 
 Micronuclei containing whole chromosomes (or chromosome fragments) have 
also been reported to induce intrachromosomal rearrangements and deletions [61]. 
Micronuclei have been suggested to induce chromothripsis [61, 84]. Chromothripsis 
occurs when a chromosome is shattered into tens or hundreds of pieces [85]. The 
chromosome pieces are eventually religated, but not always in the original order. In some 
cases a chromosome may lose DNA sequences by nuclease degradation, before religation 
can occur. Cells that undergo chromothripsis can be distinguished by three features: (1) 
complex rearrangements that are usually localized to a single chromosome or 
chromosome arm; (2) variation in gene copy number states; and (3) the loss of 
heterozygosity [85]. Chromothripsis occurs in 2-3% of all cancer cells, but has been 
reported to be as high as 25% in osteosarcoma cells. Stephen et al. sequenced 30 cancer 
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genomes and reported that the genomes in one leukemia patient and five osteosarcoma 
patients displayed the features of chromothripsis [85]. In this study, chromothripsis was 
also confirmed in 96 out 746 cancer cell lines including 3 glioma cell lines. Although 
different models have been proposed which address how chromothripsis occurs [84], 
asynchronous DNA replication that occurs in a micronucleus is the only confirmed 
mechanism [61].  
 Chromothripsis is thought to occur in micronuclei due to delays in DNA 
replication. Recall that some micronuclei do not begin DNA replication until late G2-
phase [61, 63]. Crasta et al. reported that DNA replication in micronuclei was not 
completed prior to mitosis in at least 30% of RPE-1 cells. This is a problem, because if 
DNA replication is not completed before mitosis, the chromosomes cannot be separated 
properly. Crasta et al. reported that replicating DNA that was in a micronucleus 
prematurely condensed and shattered when cells entered mitosis [61]. When the 
chromosomes were examined after religation, they contained non-reciprocal 
translocations and truncations. In addition, chromosome derivatives were detected in 
several cells, which suggest that major genomic rearrangements had occurred.  
 
1.9. Outcomes of the G2/M DNA damage checkpoint 
 Although much work has gone into characterizing micronuclei, the pathway that 
allows cells to enter mitosis with damaged DNA has not been thoroughly studied. 
Micronuclei form from cells that enter mitosis with damaged DNA; as such they are 
thought to be an outcome of checkpoint adaptation [19]. Here I will review checkpoint 
adaptation and the other outcomes of the G2/M DNA damage checkpoint.  
21 
 
 After damaged DNA has been detected and the G2/M DNA damage checkpoint 
has been engaged, one of three outcomes may occur in cells: (1) checkpoint recovery, (2) 
cell death, (3) or checkpoint adaptation.  
 Checkpoint recovery occurs when the damaged DNA is repaired. It is 
characterized by the dephosphorylation of histone γH2AX, deactivation of checkpoint 
proteins (ATM, ATR, Chk1, and Chk2), and re-entry into the cell cycle [16, 86]. 
Alternatively, if damaged DNA cannot be repaired cell death will occur through 
apoptosis (programmed cell death), necrosis, senescence, or mitotic catastrophe [19]. By 
contrast, checkpoint adaptation occurs if cells that are unable to repair damaged DNA 
after a prolonged arrest deactivate the DNA damage checkpoint and enter into mitosis 
with damaged DNA [87]. 
Importantly, checkpoint recovery and cell death prevent damaged DNA from 
being transferred to cell progeny [16]. However, during checkpoint adaptation cells have 
an opportunity to transfer damaged DNA to progeny. Therefore, damaged DNA can give 
rise to genomic change. 
 
1.9.1. Checkpoint adaptation    
 Checkpoint adaptation is defined by three steps: (1) a cell cycle arrest after 
detection of damaged DNA; (2) overcoming the arrest; and (3) re-entering the cell cycle 
with damaged DNA [87]. An overview of the steps required for checkpoint adaptation in 
human cancer cells is provided in figure 3. 
Checkpoint adaptation was first reported in studies of Saccharomyces cerevisiae 
(budding yeast) [87, 88] and was thought to be a process that could allow single-celled 
22 
 
organisms to continue dividing instead of permanently arresting if their DNA was 
damaged but not to a lethal level [87]. Sandell and Zakain reported that if a telomere was 
eliminated on a non-essential chromosome, yeast cells would undergo a cell-cycle arrest 
mediated by the checkpoint protein Rad9 [88], which is an exonuclease involved in 
sensing and repairing damaged DNA. However, after a prolonged arrest, approximately 
30% of these cells underwent cell division without repairing the broken chromosome. 
Interestingly, these cells were able to undergo up to ten cell divisions, but each time the 
chromosome size decreased, suggesting that genetic material was lost.  
 In a subsequent study, Toczyski et al. [87] reported that if a DSB was introduced 
into a mutant yeast strain defective for a DNA repair protein such as Rad52, cells would 
arrest in G2-phase for approximately 10 hours (eight times their normal cell cycle), but 
then resume cell division if the DNA damage could not be repaired.  
 Initially it was thought that checkpoint adaptation would not occur in 
multicellular organisms. In 2004, Yoo et al. reported that checkpoint adaptation could 
occur in Xenopus oocyte extracts [89]. They observed that if DNA replication was 
blocked using the DNA polymerase α inhibitor aphidicolin, cells would temporarily 
arrest in interphase and then enter mitosis despite having only partially replicated 
chromosomes. In this study, entry into mitosis was characterized by the inactivation of 
the checkpoint mediator protein claspin and the dephosphorylation of Xchk1, which is a 
homologue of human Chk1. There are several limitations with the Xenopus oocyte extract 
system, but it provided the first evidence that cells from a multicellular vertebrate are 
capable of engaging checkpoint adaptation.    
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Yoo et al. thus raised the question of whether this pathway could also occur in 
human cells [89]. One important distinction between Xenopus oocytes and somatic 
human cells is that Xenopus oocytes do not contain defined gap/growth phases, but 
instead rapidly alternate between S-phase and mitosis [90]. As such, it has been 
suggested that cell division in Xenopus oocytes progresses "unchecked" if either DNA 
replication is blocked [91] or if there is damage to the DNA [92]. Furthermore, Xenopus 
oocyte extracts are a cell free system since the cell membranes are not intact. 
 
1.9.2. Checkpoint adaptation in human cells  
 In 2006, Syljuåsen et al. reported the first observation of checkpoint adaptation in 
human cells [93]. In this study, U2OS cells were exposed to 6 Gy of ionizing radiation. 
After 20 h most cells accumulated in G2-phase. These cells were reported to contain 
histone γH2AX and Chk1 that was phosphorylated on serines 317 and 345. After 30-40 h, 
cells began to enter mitosis as determined by a rounded morphology, condensed 
chromosomes, high levels of cyclin B1, and histone H3 phosphorylated on serine 10. 
Importantly, histone γH2AX remained present in these cells, but Chk1 was 
dephosphorylated (inactive). This led Syljuåsen et al. to the hypothesis that Chk1 
dephosphorylation was required for cells to enter mitosis [93]. When Chk1 was inhibited 
with the small molecule UNC-01, the percentage of cells with damaged DNA that entered 
mitosis after 18 h increased from 2% to 12%. 
 The study conducted by Syljuåsen and colleagues had left open several critical 
questions about the relationship between damaged DNA and checkpoint adaptation.  For 
example, a lethal dose of ionizing radiation (6 Gy) was used to induce checkpoint 
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adaptation. Since humans cannot tolerate exposure to this amount of radiation it was not 
clear if this process could actually occur in the cells of a cancer patient. However, 
through a follow up study Řezáčová et al. confirmed that checkpoint adaptation occurred 
in cells exposed to a medically relevant dose of ionizing radiation (1 Gy) [94]. In this 
study, lymphocytic leukemia cells (MOLT4) were exposed to fractionated doses of 
ionizing radation (1 Gy every 24 h for a total of 96 h). Approximately 26% of cells 
arrested in G2-phase after 48 h with damaged DNA. Of the cells that entered mitosis after 
the G2-phase arrest, 76% contained damaged DNA, as measured by histone γH2AX 
detection. Importantly, this paper provided evidence that non-lethal doses of ionizing 
radiation, such as those administered to cancer patients during treatment regimens, can 
trigger checkpoint adaptation. 
 In 2012 Kubara et al. reported that both HT-29 cells and M059K cells undergo 
checkpoint adaptation in response to treatment with pharmacological concentrations of 
CPT [3]. They reported that 90% of HT-29 cells entered mitosis with damaged DNA 
after treatment with 25 nM CPT. Of the cells that entered mitosis, 2% survived. 
Consistent with previous reports, inactivation of Chk1 by dephosphorylation was 
necessary for cells to enter mitosis with damaged DNA [93, 94]. Mitotic cells were 
identified using similar methods as those used by Syljuåsen et al. (cell rounding, 
phospho-Ser10-Histone H3, and high levels of cyclin B1) [93] and by measuring Cdk1 
activity. Kubara and colleagues reported that Cdk1 did not contain the inhibitory 
phosphate on tyrosine 15 and was able to phosphorylate the substrate PP1Cα on threonine 
320 in mitotic cells. They also showed that if Cdk1 activity was blocked using the small 
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molecule CR8, cells were unable to enter mitosis and thus undergo checkpoint 
adaptation. 
 Checkpoint adaptation is very difficult to study in normal (non-cancerous) human 
cells because they have a fixed number of cell divisions, whereas cancer cell lines 
undergo an unlimited number of cell divisions. One attempt to study checkpoint 
adaptation in normal cells has been reported. Řezáčová et al. reported that normal skin 
fibroblasts exposed to 1.5 Gy of ionizing radiation entered mitosis [94]; however, most 
mitotic cells only had one or two histone γH2AX foci. Löbrich and Jeggo reported that 
the G2/M DNA damage checkpoint requires a threshold of 10-20 DSB before becoming 
activated [95]. In addition to only reporting a few histone γH2AX foci in mitotic cells, 
Řezáčová et al. did not confirm either a cell-cycle arrest or activation of Chk1 in these 
cells, which are two responses that must also occur during checkpoint adaptation. 
Therefore, it is not clear if checkpoint adaptation occurred in these cells.  
 
1.9.3. Significance of checkpoint adaptation  
 Cells that undergo checkpoint adaptation and survive generate daughter cells with 
a modified genome. Recall that chromosome size decreased in Saccharomyces cerevisiae 
with each subsequent division after checkpoint adaptation [88] and that Xenopus oocytes 
extracts entered mitosis despite that DNA replication was incomplete [89]. In both cases, 
the transfer of genomic information was not complete. 
 Kubara et al. reported that at least 2% of HT-29 cells that undergo checkpoint 
adaptation survived [3]. Analysis of cells treated with CPT showed that mitotic 
chromosomes had been shattered into several pieces [96]. Afterwards, the survivor cells 
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had an average of 35 chromosomes compared to non-treated cells, which had 65 
chromosomes. Furthermore, at least 45% of these cells were missing telomeres and 28% 
had telomere sequences that were not positioned at the chromosome ends. Although 
chromosome aneuploidy often occurs in cells that are micronucleated, micronuclei were 
not examined in this study. These data suggest that cells can acquire genomic changes 
after checkpoint adaptation.  
 During the course of anticancer treatments, both normal and cancer cells are 
exposed to DNA damaging agents. Therefore, if normal cells undergo checkpoint 
adaptation there is a potential for them to acquire genomic changes that could promote 
further mutagenesis in cells not directly associated with a primary tumour. 
 
1.10. Cancer 
 Profound genomic diversity is one of the features of cancers cells; however the 
mechanism responsible for this genomic diversity is not well understood. I will 
investigate if cells that survive checkpoint adaptation acquire genomic change. As 
described above, micronuclei are commonly found in cancer cells and are one type of 
genomic change; however, their relationship to checkpoint adaption has not been 
investigated. I will study this relationship in brain cancer cells, since they exhibit 
profound genomic diversity and are among the most difficult tumours to treat.  
 
 1.10.1 Glioblastoma multiforme 
 The Canadian Cancer Society has predicted that in 2014 approximately 2900 
Canadians will be diagnosed with a primary brain tumour and at least 1950 will die from 
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their disease [97]. The World Health Organization (WHO) has listed more than 120 
different types of brain cancers [98]. Typically, brain cancers are named after the type of 
cell from which they develop and are categorized by tumour grades (I to IV). Grades 
describe the aggressiveness and growth rate of a tumour. For example, grade I tumours 
typically describe benign or slow growing tissue, which if completely removed by 
surgical resection, do not return. By contrast, grade II to IV tumours are defined by 
malignant fast growing tissue which even after being surgically removed, often return.  
 The most common type of brain tumours are gliomas [99]. Gliomas develop from 
glial cells (non-neuronal support cells), which include astrocytes, oligodendrocytes, 
ependymocytes, and radial glia cells [100, 101]. Approximately 51% of gliomas are 
classified as being highly malignant (grade IV tumours) [101] and are referred to as 
glioblastomas multiforme (GBM). Their high rate of proliferation and aggressive 
invasiveness make GBM one of the deadliest cancers to humans worldwide [101, 102]. In 
fact, a patient with untreated GBM has a median survival time of approximately 16 
weeks after diagnosis [103]. 
 
1.10.2. GBM treatments 
 Treating GBMs is difficult. This is partly because the brain has a limited repair 
capacity and is highly sensitive to damage from genotoxic agents [100]. Furthermore, 
many anticancer drugs are unable to cross the blood-brain barrier (BBB) due to their size 
or polarity. Nearly 98% of small molecules used in treatments do not cross the BBB 
[104]. Two anticancer drugs that are used to treat GBM include CPT [105] and cisplatin 
[57, 58]. 
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 In addition to chemotherapy, GBM are also treated with a combination of surgery 
and radiation [100]. The goal of surgical resections is to remove as much of the tumour 
mass as possible, while the remaining tumour cells are targeted with chemotherapy and 
radiation. However, despite available treatments, median patient survival is only 12-14 
months [100, 101] with only 3-5% surviving more than 3 years [106].  
 
1.10.3. Significance for investigating micronuclei and checkpoint adaptation in GBM 
 To improve survival rates of GBM patients, much research has gone into 
characterizing tumours cells obtained from GBM patients with the hope of identifying 
common underlying causes. The Cancer Genome Altas (TCGA) reported that the DNA 
sequences of 206 tumours were substantially different from each other [107]. These 
differences were greater than the variations that exist in tissues from healthy individuals. 
The differences between genomes included: nucleotide substitutions, gene amplifications, 
deletions, and chromosomal rearrangements. In a follow up study another 128 tumours 
were analyzed, it was reported that their genomes also exhibited chromosome aneuploidy 
[108]. The genomic diversity and instability within these tumours cells is the likely the 
reason they respond poorly to anticancer treatments. In many cases glioblastomas initially 
respond to genotoxic treatments and either stop growing or decrease in size; however, 
cells resistant to chemotherapy and/or radiation eventually allow the tumour to continue 
growing. One hypothesis for how this occurs is that tumour cells acquire changes to their 
genome following exposure to chemotherapy and/or radiation [109]. It is therefore 
important to understand how cells acquire genomic changes so that the mechanisms 
responsible can be targeted.  
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1.10.4. Checkpoint adaptation and glioblastoma cells 
 Several studies have confirmed the activation of the DNA damage checkpoint in 
glioblastoma cells following genotoxic treatment [110], however few studies have 
examined the events that occur after the DNA damage checkpoint is activated. I propose 
that glioblastoma cells undergo checkpoint adaptation and acquire genomic changes such 
as micronuclei. 
 Micronuclei are commonly observed in glioblastoma cells following genotoxic 
treatment [111, 112]. Akudugu and Böhm reported that five glioblastoma cell lines 
(G120, G60, G28, G44, and G62) formed micronuclei after exposed to ionizing radiation 
[111]. At a therapeutic dose of 2 Gy approximately 25-50% of these cells acquired 
micronuclei [111]. In another study of 8 human glioblastoma cell lines, Slowinski et al. 
observed micronuclei after exposure to 2 Gy of ionizing radiation [112]. In this study 
78% of DK-MG cells that underwent mitosis produced at least one daughter cell with a 
micronucleus. Importantly, these studies did not confirm if the DNA damage checkpoint 
was active or if cells entered mitosis with damaged DNA prior to cell death, therefore it 
is not known if checkpoint adaptation occurred.  
 Checkpoint adaptation has been reported to occur in a glioblastoma cell line 
(M059K) following treatment with CPT [3]. Evidence of checkpoint adaptation was also 
reported in another glioblastoma cell line (U87MG-E6) [113]. In this study, mitotic death 
occurred in cells treated with the DNA methylating agent temozolomide (TMZ) after a 
prolonged arrest in G2-phase, but there was no confirmation of damaged DNA in mitotic 
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cells. Importantly, micronuclei were not reported in either of the studies using M059K 
cells or U87MG-E6 cells. 
 
1.10.5. M059K cells 
 M059K cells have been previously established as a cellular model for checkpoint 
adaptation in our laboratory [3]. They exhibit several chromosomal rearrangements [114], 
contain a variable chromosome number (65 to 79), and at least 22% of cells are polyploid 
[115]. Cells treated with 25 nM CPT recruited histone γH2AX and contained Chk1 
phosphorylated on serine 345 [3]. Approximately 48 h post treatment, cells accumulate in 
G2-phase of the cell cycle as determined by flow cytometry. After accumulating in G2-
phase, cells begin to enter mitosis as detected by cell rounding, and by the presence of the 
phospho-Ser10-histone H3. While in mitosis, cells retained histone γH2AX and 
dephosphorylated Chk1.   
 M059K cells have also been previously shown to acquire micronuclei following 
exposure to silver nanoparticles (Ag-np) [116]. Ag-np induced DSB and chromosome 
aberrations including acentric and dicentric chromosomes. Lim et al. reported that cells 
treated with 100 µg/mL of Ag-np form 50% more micronuclei than non-treated cells 
[116]. Therefore, even novel genotoxic agents can induce micronuclei. Because M059K 
cells form micronuclei in the presence of damaged DNA and undergo checkpoint 
adaptation they are a useful model to study the relationship between these processes. 
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Chapter 2 - Introduction 
The prognosis for glioblastoma patients is dismal, with an average survival rate of 
12 to 14 months [100, 101] and a 3 year survival of only 3% to 5% even after treatment 
with radiation and chemotherapy [106]. It has been suggested that existing treatments 
may be ineffective due to the profound genomic diversity present in glioblastoma cells 
[107]. After sequencing the tumour genomes from 206 glioblastoma patients, The Cancer 
Genome Atlas (TCGA) reported that every genome had different combinations of 
nucleotide substitutions, gene amplifications, deletions, and chromosomal rearrangements 
[107]. In follow-up study of another 128 glioblastomas, chromosome aneuploidy was 
also reported in the tumour genomes [108]. To improve patient outcome, it is necessary 
to understand how these differences arise in glioblastoma genomes. 
One way cells can acquire genomic change is through checkpoint adaptation 
(mitosis with damaged DNA) [16, 19]. In 2012, it was reported that human glioblastoma 
cells (M059K) underwent checkpoint adaptation following treatment with 25 nM 
camptothecin (CPT) [3]. CPT is a topoisomerase I inhibitor, which is used to treat 
glioblastoma patients [105]. 
Checkpoint adaptation is characterized by a cell-cycle arrest after detection of 
damaged DNA, overcoming this arrest and entry into mitosis with damaged DNA [87]. 
Cells signal the presence of damaged DNA by activating histone γH2AX [22, 23]. This 
leads to the activation of the DNA damage checkpoint, which is characterized by the 
phosphorylation of checkpoint kinase 1 (Chk1) on serine 345 [14]. Phospho-Ser345-Chk1 
prevents the activation of Cdk1 by up-regulating the activity of Wee1 [36] and down-
regulating the activity of Cdc25C [35]. This causes cells to arrest in G2-phase with 4n 
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DNA [33]. Eventually, cells enter mitosis despite having high levels of histone γH2AX 
[3, 93]. Mitosis can be detected by the presence of cyclin B1 and activation of cyclin-
dependent kinase 1 (Cdk1) [5, 6].  
Although most cells that undergo checkpoint adaptation die, at least 2% survive 
[3]. Survivor cells have been reported to contain fewer chromosomes, which are smaller 
in size and have telomeres that are either missing or at positions other than the 
chromosome ends [96].  
Several studies have demonstrated that genotoxic treatments can induce 
micronuclei, another type of genomic change. Micronuclei form from lagging anaphase 
whole chromosome [61, 62] or chromosome fragments [63] that did not attach properly 
to the spindle apparatus. This can occur if the centromere is either damaged [64, 71, 72] 
or missing [71, 74] as is the case for acentric chromosome fragments. In addition, 
damaged chromosomes may fuse and create a dicentric chromosome [71], which 
becomes attached to both spindle poles. Dicentric chromosomes form a nucleoplasmic 
bridge (NPB) between daughter nuclei after anaphase. The NPB is subsequently broken 
in cytokinesis and the resulting DNA fragments are then incorporated into micronuclei.  
Once present, micronuclei induce additional damage to DNA. In 2012, Crasta et 
al. reported that chromosomes inside micronuclei acquire DNA breaks and, in some 
cases, undergo chromothripsis (chromosome shattering) due to aberrant DNA replication 
[61]. This process can be detected by the asynchronous incorporation of 5-bromo-2’-
deoxyuridine (BrdU) in place of thymine during DNA replication and by the presence of 
histone γH2AX foci in the micronuclei [61, 63]. Chromosomes that undergo this process 
are shown to acquire genomic changes including translocation and truncations [61]. 
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Despite the formation of micronuclei from cells that enter mitosis with damaged 
DNA, the relationship of micronuclei to checkpoint adaptation has not been studied. This 
is mainly because checkpoint adaptation was only recently observed in human cancer 
cells. In this thesis I will determine if the formation of micronuclei requires checkpoint 
adaptation [63, 71]. To study this relationship I will examine M059K cells since they 
have been previously shown to undergo checkpoint adaptation. Furthermore, these cells 
have also been reported to form micronuclei after genotoxic treatment with silver 
nanoparticles (Ag-np) [116].  
In addition to determining the relationship between micronuclei and checkpoint 
adaptation in M059K cells, I will also determine if either of these processes occurs in the 
normal lung fibroblast cell line (WI-38). Checkpoint adaptation has not been reported in 
normal cells. Normal cells are difficult to culture and have a limited number of cell 
divisions [117]. 
WI-38 cells contain two functional DNA damage checkpoints that regulate the 
transition between G1/S and G2/M-phases. At least 80% of cancer cells (including 
M059K cells) have a defect in the p53 pathway [17], which impairs the activation of the 
G1/S DNA damage checkpoint. This causes M059K cells to accumulate in G2-phase with 
damaged DNA, a response that is required for checkpoint adaptation [3]. Since WI-38 
cells have a functional G1/S DNA damage checkpoint, it is not known if they can 
undergo checkpoint adaptation.  Understanding if checkpoint adaptation can occur in 
normal cells is important since genomic instability in normal cells may contribute to the 
development of secondary tumours; a process that commonly occurs in glioblastoma 
patients. 
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 Research Objectives 
 The main objective of this thesis is to determine if checkpoint adaptation is 
required for the formation of micronuclei in human cancer cells. Checkpoint adaptation 
and the formation of micronuclei have been reported in human cancer cells with damaged 
DNA; however the relationship between these processes has not been studied. To study 
this relationship, it will be necessary to complete the following:  
1. Develop an experimental model to study micronuclei using a glioma cell line 
(M059K) and compare them to a normal cell line (WI-38). This is important 
because many cancer cells already have micronuclei and therefore it is 
necessary to characterize how many are micronucleated before genotoxic 
treatment.   
2. It is not known to which genotoxic molecule the M059K and WI-38 cells will 
be sensitive to, therefore it is necessary to characterize different genototxic 
molecules (CPT, S23906-1, and cisplatin). Then I will test if the selected 
genotoxic agent induces micronuclei in M059K cells.  
3. If micronuclei form in M059K cells, I will test if cells also exhibit the steps of 
checkpoint adaptation: signal damaged DNA, activate Chk1, accumulate in 
G2 phase, and enter into mitosis with damaged DNA.  
4. I will examine if WI-38 cells undergo the steps of checkpoint adaptation 
and/or form micronuclei. This is important because checkpoint adaptation has 
not been reported in normal cells. Answering this question is important in 
explaining how normal cells become cancerous. 
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Chapter 3 - Materials and methods 
 
3.1. Cell Culture 
 Human M059K and WI-38 cells were obtained from the American Type Culture 
Collection (CRL-2365; CCL-75). M059K cells were maintained in Dulbecco’s Modified 
Eagle medium (DMEM) F-12 (Gibco; 11320-082), supplemented with 10% heat 
inactivated fetal calf serum (Gibco; 12484028), 2 mM non-essential amino acids (Gibco; 
11140050), and 15 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 
pH 7.4. WI-38 cells were maintained in DMEM/high glucose (Sigma; D6546) 
supplemented with 10% heat inactivated fetal calf serum (Gibco; 12484028), 2 mM non-
essential amino acids (Gibco; 11140050), and 1.6 mM GlutaMAX (Gibco; 35050-061). 
Cells were grown at 37°C in 5% CO2 and media was changed every three to four days.  
M059K and WI-38 cells were plated at a density of 5.0 x 105 cells/75 cm2 flask and 
cultured for 48 h prior to treatment. The compound cisplatin (Sigma; 479306-1G) was 
dissolved in dimethyl sulfoxide (DMSO) (Sigma; D2438) to a concentration of 100 mM. 
CR8 (Tocris Biosciences; 2706/10), Gö6976 (Tocris Biosciences; 2253), CPT (Sigma; 
7689-03-4) and S23906-1 (Servier) were dissolved to a concentration of 10 mM. 
Nocodazole (Sigma-Aldrich; M1404-10MG), and aphidicolin (Santa Cruz; sc-201535) 
were dissolved in DMSO at concentrations of 200 μg/mL and 10 mg/mL respectively. All 
compounds listed were stored at -20°C until use. 
 
  
36 
 
3.2. Cytotoxicity Assay 
 Cytotoxicity of CPT, S23906-1, and cisplatin on M059K and WI-38 cells was 
measured by the micro-culture tetrazolium assay (MTT; (3-(4,5)-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (Sigma-Aldrich; M2128-1G)) [3, 118]. Cells were 
plated at 4.0 x 105 cells/96 well assay plate and cultured for 48 h prior to treatment. All 
measurements were performed in triplicate at 48 h and 96 h unless otherwise indicated. 
After the desired treatment time, 20 µL of MTT solution (5 mg/mL of MTT in PBS) was 
added to each well without removing media for 3.5 h. Afterwards, the media was 
aspirated and 100 µL of MTT solvent (4 mM HCl, 0.1% IPEGAL 
(octylphenoxypolyethoxyethanol), in isopropanol) added. Plates were placed on shake 
tray for 20 min and then the absorbance of each well was measure at 590 nm using the 
BioTek™ microplate spectrophotometer powered by Eon™ software. Results were 
expressed as IC50 concentrations; the genotoxic molecule concentration that reduced 
absorbance of the MTT by 50%, compared to 0.1% DMSO treated cells. The normalized 
percent absorbance was calculated using the equation: 
 Normalized % absorbance = (absorbance/DMSO absorbance) x 100% 
The log concentration of the genotoxic molecule was then plotted against the normalized 
percent absorbance and analyzed by GraphPad Prism 5 software using non-linear 
regression (log (inhibitor) versus normalized response) to estimate the IC50 
concentration. Standard curves were then plotted using the equation: 
Y = maximum + (maximum - minimum) / (1 + 10X - LogIC50) 
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Where the maximum is the percentage of viable cells after treatment with 0.1% DMSO 
and the minimum is the percentage of viable cells after treatment with the highest 
concentration of the genotoxic molecule.  
 
3.3. Flow Cytometry 
 After desired treatment time, total cell cultures were trypsinized, washed in 
phosphatase-buffered saline (PBS) (137 mM NaCl, 3 mM KCl, 100 mM Na2HPO4, 18 
mM KH2PO4) and fixed in 90% ethanol (-20°C) for at least 24 h. Fixed cells were rinsed 
once with PBS and twice with wash buffer (PBS, 1% BSA, 0.1% sodium azide) [3].  For 
analysis, samples were incubated for 20 min in wash buffer containing 0.02 mg/mL 
propidium iodide (Life Technologies; P1304MP) and 0.2 mg/mL RNAse A (Sigma; 
R6513-250MG), and analyzed with a FACS Canto II™ flow cytometer (BD Biosciences) 
using BD FACSDiva™ software. Gating was set using non-treated and nocodazole 
samples. Experiments were repeated at least twice. 
 
3.4. Extract preparation  
 Cells were trypsinized,  passed through a 26 gauge needle 5 times, and 
resuspended in extraction buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), pH 7.4, 50 mM NaF, 10 mM EGTA (ethyleneglycol-bis(beta-
aminoethylether)-N,N′-tetraacetic acid), 50 mM β-glycerophosphate, 1 mM ATP, 1 mM 
(DTT) dithiothreitol, 1% Triton X-100, 10 μg/mL RNAse A (Sigma; R6513-250MG), 0.4 
U/mL DNAse I (Invitrogen, I354Ba), with protease inhibitors (Roche; 11836170001)) at 
a concentration of 20,000 cells/μL on ice for 30 min. The suspension was centrifuged at 
38 
 
10,000×g for 10 min at 4 °C [3]. Extracts were boiled for 5 min in the presence of 2× 
SDS sample buffer (20% Glycerol, 10% DTT, 6% SDS, 500 mM Tris, pH 6.84). 
 
3.5. Electrophoresis and western blotting 
 Reaction mixtures were separated in triplicate on an 8% SDS gel with a 4% 
stacking gel at 200 volts for 35 min. Proteins were transferred to nitrocellulose with a wet 
electroblotter system (BioRad) for 17.5 h at 30 volts and 90 mA. Subsequently, the 
membrane was blocked with either 5% low fat milk in Tris buffered saline TBS-0.1% 
Tween-20 (TBST) or 2% BSA in TBS-0.1% Tween-20 (TBS-T), and incubated overnight 
with the indicated primary antibody as follows: anti-Chk1 (Santa Cruz; SC-8408; 1:200), 
anti-phospho ser345 Chk1 (Cell Signalling; 2348S; 1:2000), or anti-actin (Santa Cruz; sc-
58673; 1:200). After washing, the membrane was incubated with alkaline phosphatase-
coupled anti-mouse (Promega; S3721; 2500) or anti-rabbit antibodies (Millipore; 
AP132A; 1:2500). Western blots were performed at least two times [3, 10]. 
 
3.6. Immunofluorescence microscopy 
 Cells were plated on glass coverslips for 48 h prior to treatment, then fixed in 3% 
formaldehyde for 20 min at room temperature.  Cells were quenched with 50 mM NH4Cl 
in PBS, permeabilized for 5 min in 0.2% Triton X-100, and blocked with 3% BSA for 30 
min. Cells were incubated with primary antibodies for 2 h at room temperature as 
follows: anti-histone γH2AX (Millipore; 05-636; 1:400), anti-cyclin B1 (Santa Cruz; SC-
752; 1:100), or anti-lamin A/C (Santa Cruz; SC-6215; 1:150). After washing, cells were 
incubated with secondary antibodies at room temperature for 2 h as indicated: Alexa488 
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anti-mouse (Life Technologies; A11059; 1:400) for anti-histone γH2AX, Alexa488 anti-
rabbit for cyclin B1 (Life Technologies; A11008; 1:400), and Alexa488 anti-goat (Life 
Technologies; A11059; 1:150) for anti-lamin A/C. Nuclei were stained with 300 nM 4',6-
diamidino-2-phenylindole (DAPI) in PBS for 15 min prior to mounting [3].  Cells were 
observed on an Olympus microscope operated by Infinity Capture Imaging software. 
Images were collected by the Infinity3 camera within the linear dynamic range. The 
linear dynamic range represents the range in which the relationship between a signal 
intensity and amount of material is likely to be linear. Images were prepared with ImageJ 
(IJ 1.46r) and Adobe Photoshop (CS3 10.0) software. Cells positive for histone γH2AX, 
cyclin B1, or Lamin A/C were counted using ImageJ (IJ 1.46r) software. At least 200 
cells were counted per experiments and experiments were repeats at least twice. 
 
3.7. Scoring micronuclei 
 Micronucleated cells, individual micronuclei, and nucleoplasmic bridges (NPBs) 
were counted manually from DAPI stained cells. DAPI positive micronuclei were 
confirmed by additional staining methods: lamin A/C, histone γH2AX, or BrdU. At least 
200 cells were counted for each experiment and experiments were repeated at least twice. 
Criteria for scoring micronuclei included the following: (1) separate (non-overlapping) 
extra-nuclear structures that were positive for  DAPI; (2) intensity of DAPI staining in 
micronucleus did not exceed the main nucleus; (3) encased by nuclear envelope 
composed of the protein lamin A/C; and (4) a rounded shape [71, 78, 119]. DAPI staining 
intensity and shape of micronuclei were confirmed by visual observations. 
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3.8. 5-bromo-2’-deoxyuridine (BrdU) assay 
 Cells were pre-labelled with 10 μM BrdU for 1 h at 37°C and then fixed with 
ethanol and permeabilised according to the manufacturers’ conditions (5-bromo-2-
deoxyuridine Labelling and Detection Kit 1; Roche; 11296736001). Cells were then 
stained with anti-BrdU for 1 h at 37°C (1:10) and then incubated with the anti-mouse-Ig-
fluorescein secondary antibody for 1 h at 37°C (1:10). Slides were then processed for 
immunofluorescence [61]. 
 
3.9. Statistics 
 Graphing and statistics were completed using Microsoft Excel 2010 software.  
Data were collected and plotted as means ± standard error of the means. Significance was 
determined using ANOVA and student t-test for two paired sample means unless 
otherwise indicated. 
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Chapter 4 - Results 
To examine the relationship between damaged DNA, checkpoint adaptation, and 
micronuclei, I organized experiments into four parts: (1) develop a new experimental 
model using glial cancer cells; (2) measurement of micronuclei formation under different 
treatment conditions; (3) testing the relationship between damaged DNA and 
micronuclei; and (4) examine micronuclei in a non-cancer cell line. 
 
4.1. Characterization of micronuclei in glial cancer cells 
It was important to characterize our experimental model prior to performing 
experiments because most cancer cells already contain micronuclei [71, 73, 120]. 
Therefore, I first determined the percentage of M059K cells with either micronuclei or 
nucleoplasmic bridges (NPB). Micronuclei were defined as separate (non-overlapping) 
extra-nuclear structures with a rounded shape that contained DNA encased by a nuclear 
envelope composed of the protein lamin A/C [61, 63, 71, 119, 121-123]. I stained cells 
with DAPI to detect DNA and observed them by immunofluorescence microscopy 
(Figure 4). I then counted rounded extra-nuclear structures that were DAPI positive. In an 
exponentially growing culture of M059K cells, 25% ± 1% contained at least one DAPI 
stained structure in addition to the main nucleus. Cells also had NPBs but at a much 
lower frequency (0.5% ± 0.1%). To confirm that the DAPI positive structures were 
contained by a nuclear envelope, I stained cells with an anti-lamin A/C antibody. I 
examined 200 micronucleated cells and confirmed that 94% ± 8% of extra-nuclear 
structures identified by DAPI also contained lamin A/C. This experiment was repeated 
twice. Since almost all DAPI structures had lamin A/C, it was not required for subsequent 
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experiments for identifying micronuclei in these cells. Therefore, in our experimental 
model, approximately 24% of the M059K cells have micronuclei, which is consistent 
with a cancer phenotype [116, 124-127]. If checkpoint adaptation is linked to micronuclei 
production, then I could expect that there will be changes in either the number of cells 
that have micronuclei and/or NPBs, or the number of micronuclei and/or NPBs in cells 
that undergo checkpoint adaptation. 
Micronuclei are rarely detected in normal, non-cancerous human cells [126, 128]. 
I confirmed this by examining the normal human lung cell line WI-38, which are 
fibroblastic, as are M059K cells. I was obliged to use lung cells since normal neural cells 
are extremely difficult to cultivate. Cells were stained with either DAPI or anti-lamin A/C 
antibodies and observed by immunofluorescence microscopy (Figure 5). In contrast to 
M059K cells in which 25% ± 1% had DAPI stained structures, only 2% ± 2% of WI-38 
cells contained DAPI stained structures. No NPBs were detected in these cells. Cells 
were also analyzed for the presence of lamin A/C, but only 47% ± 5% of extra-nuclear 
DAPI stained structures were lamin A/C positive. Since over half of extra-nuclear DAPI 
stained structures in WI-38 cells were not enclosed by a nuclear envelope, they were not 
considered to be true micronuclei [61, 67, 78, 129]. These results confirmed that normal 
cells have few micronuclei [126], compared to cancer cells. 
 
4.2. Characterization of genotoxic agents 
To test the relationship between a genotoxic treatment and changes in the status of 
micronuclei, I first needed to select a genotoxic agent for use in our experiments. I tested 
three agents, camptothecin (CPT), S23906-1, and cisplatin (Table 1), with a different 
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mechanism of action. Our criteria for selection were an agent that has an IC50 
concentration to cultured cells that was similar to the concentration used to treat human 
cancer patients [19, 130], and a difference in cell viability between early and late times 
after treatment [3]. Different concentrations of either CPT, S23906-1, or cisplatin were 
added to cells and cell viability was measured at 48 h and 96 h by the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (Figure 6; Table 2). Data 
were normalised to those obtained by treatment with 0.1% DMSO, which was the 
solvent. I observed that cell viability declined in both M059K cells and WI-38 cells as the 
concentration of each genotoxic agent was increased; the lowest viability was observed at 
96 h and the highest viability was observed at 48 h. I found that M059K cells treated with 
CPT had IC50 values of 49.4 nM at 48 h and 7.4 nM at 96 h. WI-38 cells were less 
sensitive to CPT and had IC50 values of 376.4 nM at 48 h and 94.6 nM at 96 h. Whereas 
the IC50 value of CPT after 96 h in M059K cells was within the pharmacologically 
relevant concentration range (2.8-17.3 nM) [131], the IC50 concentration in WI-38 cells 
was five times higher than the maximum concentrations received by human patients. CPT 
was therefore excluded from further experiments. M059K cells treated with S23906-1 
had IC50 values of 7.6 μM at 48 h and 2.2 μM at 96 h; these concentrations were within 
the cytotoxic range of previously published IC50 values (1-10 µM) [51, 52, 132, 133]. 
WI-38 cells were less sensitive to S23906-1. The calculated IC50 values were 48.1 μM at 
48 h and 14.8 μM at 96 h, which were outside our experimental treatment range (0.01-10 
μM) and were higher than concentrations previously published. On the basis of this, 
S23906-1 was also excluded from further testing. M059K cells treated with cisplatin had 
IC50 values of 58.8 μM at 48 h and 15.4 μM at 96 h. By contrast, WI-38 cells treated with 
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cisplatin had an IC50 value 12 times higher than M059K cells at 48 h (681 μM), but had a 
similar IC50 value of 18.5 μM at 96 h. Based on these data, 30 μM cisplatin was selected 
for subsequent experiments because it was a cytotoxic concentration in both M059K cells 
and WI-38 cells and was within the pharmacologically relevant treatment range (12-40 
μM) for human cancer patients [19, 134-136]. I noted that 40% ± 5% of M059K cells and 
40% ± 11% of WI-38 cells treated with 30 μM cisplatin for 96 h were still alive. To 
further demonstrate the cytotoxicity of 30 μM cisplatin, I treated cells with cisplatin for 
an additional 24 h (120 h total). I observed that cell viability declined to 19% ± 5% in 
M059K cells and 27% ± 2% in WI-38 cells treated with cisplatin for 120 h indicating that 
longer treatments with cisplatin results in more cell death. Importantly, at this 
concentration 80-90% of cells were alive at 48 h, but most (73-81%) had died by 120 h. 
This type of cellular response is characteristic of checkpoint adaptation [3], a point that 
will be described later in my thesis. Based upon the outcome of these tests, I then selected 
cisplatin as the genotoxic agent to investigate micronuclei. 
 
4.3. Cisplatin induces micronucleation in M059K cells 
 Having confirmed that cisplatin induced the desired cytotoxic response in M059K 
cells, I then tested if treatment with cisplatin would increase either the number of cells 
that had micronuclei and/or NPBs, or the number of micronuclei and/or NPBs per cell. 
Cells were treated with 30 μM cisplatin for up to 120 h and then stained with DAPI and 
observed by immunofluorescence microscopy (Figure 7A).  I observed that the 
percentage of cells with micronuclei was 24% ± 2% at time 0, but doubled to 48% ± 7% 
by 96 h ((t = 2.13; d.f. = 4; p < 0.05) Figure 7B). I also observed an increase in the 
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number of micronuclei per cell (Figure 7C). At time 0, 72% ± 2% of the micronucleated 
cells had one micronucleus whereas only 2% ± 0.4% of cells had six or more 
micronuclei. However, after 120 h the percentage of cells with one micronucleus dropped 
to 47% ± 1% and those containing six or more micronuclei had significantly increased to 
33% ± 1% (t = 2.13; d.f. = 4; p < 0.05). The number of cells containing two to five 
micronuclei did not change in a significant manner. I also observed additional NPBs. 
Between 0 and 72 h, the proportion of cells with NPBs was less than  1%, but after 120 h 
they had increased to 3% ± 1% (t = 2.13; d.f. = 4; p < 0.05). These data confirm that 
treatment with cisplatin induces the formation of micronuclei in M059K cells, an 
observation that had been previously reported in experiments using other human cancer 
cells [64, 68, 137]. Having observed that an increase in treatment time led to an increase 
in micronucleation, I then tested the effects of increases in cisplatin concentrations. Cells 
were either non-treated or treated with 10-300 μM cisplatin for 48 h, and then stained for 
DNA and observed by immunofluorescence. I observed that the percentage of cells with 
micronuclei increased from 23% ± 1% in non-treated cells to 60% ± 8% in cells treated 
with 300 μM cisplatin (t = 6.31; d.f. = 1; p < 0.05 (Figure 8)). These data demonstrate a 
dose-dependent response between cisplatin and micronuclei formation.  
 
4.4. Micronuclei persist for at least eight days after treatment with cisplatin 
 Knowing that cisplatin increased the percent of cells with micronuclei, I examined 
whether the micronuclei that formed persisted after cisplatin treatment. I treated M059K 
cells with 30 μM cisplatin for 120 h, and then cultured them for an additional 8-10 days 
with fresh (non-treated) media. Cells were then stained with DAPI and observed by 
46 
 
immunofluorescence microscopy (Figure 9). I observed that the percentage of 
micronuclei in surviving cells (cells analyzed 8 to 10 days after cisplatin removal), was 
significantly higher than in non-treated cells, 47% ± 6% compared to 23% ± 5% (t = 
2.02; d.f. = 5; p < 0.05). Interestingly, the percentage of surviving micronucleated cells 
remained at a similar level to that of cells analyzed directly after treatment with 30 µM 
cisplatin for 120 h (Figure 7). Together, these data suggest that once a micronucleus is 
formed, it can be stably maintained in cells for at least 8-10 days after cisplatin treatment 
is stopped. 
 
4.5. Micronuclei arise in M059K cells that have undergone checkpoint adaptation 
Since M059K cells treated with cisplatin formed additional micronuclei, I then 
asked if this increase required checkpoint adaptation. Checkpoint adaptation is composed 
of three steps: (1) an arrest in G2-phase following detection of damaged DNA; (2) bypass 
of the G2-phase arrest; and (3) entry into mitosis in the presence of damaged DNA [87]. I 
prepared a series of experiments to investigate if these steps had occurred.  
Cells that undergo checkpoint adaptation signal the presence of damaged DNA 
through the phosphorylation of the histone variant H2AX on serine 139, then becoming 
γH2AX. M059K cells were either non-treated or treated with different concentrations of 
cisplatin (10 μM to 300 μM) and then stained with DAPI and anti-histone γH2AX 
antibodies for detection of DNA and damaged DNA, respectively (Figure 10A). I 
observed that both the number of cells positive for histone γH2AX and intensity of 
histone γH2AX staining increased with an increase in the concentration of cisplatin. No 
histone γH2AX signals were detected in non-treated cells. The percentage of cells that 
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were positive for histone γH2AX after treatment with 10 μM cisplatin was 61% ± 3%, 
but this percentage significantly increased to 94% ± 2% with higher concentrations of 
cisplatin (30 μM to 300 μM) ((t = 6.31; d.f. = 1; p < 0.05) Figure 10B). These data are 
consistent with previously published reports [52, 138], which show that cisplatin 
damages DNA, a response necessary for the first step of checkpoint adaptation [3].  
Damaged DNA leads to a second checkpoint adaptation response: 
phosphorylation of checkpoint kinase 1 (Chk1) on serine 345. This phosphorylation 
activates Chk1 and causes cells to initiate a cell-cycle arrest. To examine this, I prepared 
protein extracts from M059K cells that were either non-treated or treated with 30 μM 
cisplatin for 24 h and then tested them for phospho-Ser345-Chk1 by western 
blotting (Figure 11A). Phospho-Ser345-Chk1 was present in cells treated with cisplatin, 
but absent in non-treated cells. Comparison of non-phosphorylated Chk1 levels in treated 
and non-treated cells confirmed that the total amount of Chk1 protein were similar. 
Comparison of actin levels between extracts confirmed equal loading of proteins. These 
data indicated that cells treated with 30 μM cisplatin activate Chk1, which is also 
necessary for the first step of checkpoint adaptation.   
I then examined if a cell-cycle arrest had occurred in cisplatin-treated cells by the 
technique of flow cytometry, which measures DNA content. M059K cells were either 
non-treated, treated with 200 ng/mL of nocodazole (G2/M-phase control), or treated with 
30 μM cisplatin, and then analyzed at 24 h by flow cytometry (Figure 11B and C). As 
expected, non-treated cells were predominantly in the G1-phase (67% ± 1%) with the 
remaining cells in either the S-phase (14.6 ± 1%) or G2/M-phase (18% ± 2%) [3]. By 
contrast, 49% ± 1% of cells treated with nocodazole were in the G2/M-phase [3]. 
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Treatment with cisplatin resulted in 47% ± 1% of cells in G1-phase, 24% ± 0.3% cells in 
S-phase, and 29% ± 1% cells in G2/M-phase, which confirmed that a cell-cycle arrest had 
occurred in some cells[139].  
Having shown that M059K cells treated with cisplatin had damaged DNA, active 
Chk1, and had undergone a cell-cycle arrest, I then examined the population for mitotic 
cells. This was important because in the final step of checkpoint adaptation, cells enter 
mitosis with damaged DNA [87]. I first tested if cells contained the cyclin B1, which is 
an essential protein that forms a complex with the mitotic enzyme cyclin dependent 
kinase 1 (Cdk1) [6]. Cells were either non-treated or treated with 30 μM cisplatin for 48 h 
and then stained for cyclin B1 and observed by immunofluorescence microscopy (Figure 
12). In non-treated cell populations, only 13% ± 3% of cells were cyclin B1 positive. By 
contrast, treatment with 30 μM cisplatin for 48 h increased the percentage of cyclin B1 
positive cells to 75% ± 3% (t = 6.31; d.f. = 1; p < 0.05). The accumulation of cyclin B1 
positive cells following cisplatin treatment suggests that these cells were “primed” for 
entry into mitosis despite the fact that 94% ± 2% had damaged DNA at 48 h (Figure 10).  
The analysis of cyclin B1 and histone γH2AX revealed that most cells were 
competent to enter mitosis with damaged DNA. Under the current model of checkpoint 
adaptation, the inhibition of either Chk1 or Cdk1 with chemical inhibitors can be used 
control the number of cells that enter into mitosis. 
Chk1 controls the DNA damage checkpoints that are responsible for the cell-cycle 
arrest. Inhibiting Chk1 activity causes cells to enter mitosis with damaged DNA [40]. I 
tested if blocking the activity of Chk1 with the small molecule Gö6976 [140] would 
result in an increase in micronucleated M059K cells. Cells were either non-treated, 
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treated with 15 nM Gö6976 for 24 h, 30 μM cisplatin for 48 h, or with 30 μM cisplatin 
for 24 h and then co-treated with 15 nM Gö6976 for an additional 24 h. Cells were 
stained with DAPI and then observed by immunofluorescence microscopy (Figure 13). I 
observed that 28% ± 1% cisplatin-treated cells had micronuclei. By contrast, 38% ± 3% 
of cells co-treated with Gö6976 and cisplatin had micronuclei, which represented a 
significant increase (t = 2.92; d.f. = 2; p < 0.05). There was no significant change in the 
percentage of cells with micronuclei after treatment with Gö6976 alone compared to non-
treated cells (t = 2.92; d.f. = 2; p = 0.052). These data suggest that inhibiting Chk1 
enables more cells with damaged DNA to enter mitosis and subsequently form new 
micronuclei.  
Having shown that enabling cells to enter mitosis with damaged DNA increases 
the number of micronuclei, I then tested if preventing mitosis in cells with damaged DNA 
would stop new micronuclei from forming. Cdk1 controls entry into mitosis. Inhibiting 
Cdk1 with CR8 prevents cells with damaged DNA from entering mitosis [3]. Cells were 
treated with either 30 μM cisplatin or co-treated with 30 μM cisplatin and 500 nM CR8 
for up to 120 h. Cells were then stained with DAPI and observed by immunofluorescence 
microscopy (Figure 14). As shown in Figure 7, treatment with cisplatin increased the 
percentage of micronucleated cells over time. By contrast, no significant change in 
micronucleation was observed in the cell population that was co-treated with cisplatin 
and CR8. This confirmed our prediction that cells with damaged DNA cannot form new 
micronuclei if Cdk1 activity is blocked. 
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4.6. Micronuclei undergo aberrant DNA replication  
In 2012, Crasta et al. examined micronuclei in RPE-1 (epithelial) and U2OS 
(osteosarcoma) cells and showed that DNA in micronuclei is damaged by aberrant DNA 
replication [61]. They showed that DNA replication in micronuclei was not synchronized 
with the DNA replication in the main nucleus. They also showed that DNA replication 
induced histone γH2AX foci in micronuclei. Since I had an established experimental 
model that had a high percentage of cells with micronuclei, I was well poised to extend 
the observations by Crasta et al. [61]. To examine if DNA in the micronuclei of M059K 
cells undergoes asynchronous DNA replication and if replication damages the DNA I 
designed a series of experiments in three steps: (1) characterization of DNA replication in 
micronuclei; (2) examination of micronuclei for damaged DNA; and (3) testing the 
relationship between replication and damaged DNA in micronuclei.   
It was not known whether the DNA of micronuclei in M059K cells would 
undergo DNA replication, therefore I first needed to answer this. I examined DNA 
synthesis by a method that measures the incorporation of the nucleoside analogue 5-
bromo-2’-deoxyuridine (BrdU) in place of thymidine during DNA replication. Cells were 
incubated with 30 μM BrdU for 30 min and then stained with DAPI and anti-BrdU 
antibodies and observed by immunofluorescence microscopy (Figure 15). I detected 
BrdU incorporation in 35% ± 4% of non-treated cells, consistent with cell-cycle phase 
values obtained by flow cytometry (Figure 11B and C). I observed that BrdU signals in 
the micronucleus and main nucleus were not correlated in 20% ± 7% of non-treated cells 
(Table 3). These cells were either positive for BrdU in the micronucleus and not in the 
main nucleus or vice versa.  
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To address if DNA in micronuclei was damaged, I then examined micronuclei for 
histone γH2AX. Consistent with previously published reports [61], I detected that 47% ± 
9% of micronuclei in non-treated cells were positive for histone γH2AX staining whereas 
the main nuclei were negative for histone γH2AX staining (Figure 16, Table 4). These 
data support that the DNA in micronuclei can be damaged in the absence of genotoxic 
treatment with cisplatin, and that this damage might be caused by DNA replication. 
To test whether DNA replication was inducing damaged DNA in micronuclei, I 
set up experiments to block DNA replication using aphidicolin (APH), a DNA 
polymerase α inhibitor [141, 142]. First, I needed to determine the optimal APH 
concentration that could inhibit DNA replication in these cells. Cells were non-treated, 
treated with 200 ng/mL of nocodazole to set a 4n DNA amount, or treated with 0.1 
μg/mL, 1 μg/mL, and 10 μg/mL of APH for 24 h and then analyzed by flow cytometry 
for DNA content (Figure 17). Higher APH concentrations resulted in fewer cells in S-
phase and G2/M-phase compared to non-treated cells (Figure 17B). Treatment with 10 
μg/mL APH resulted in the highest amount of cells in G1-phase (82% ± 3%), which 
suggested that DNA replication was blocked. Therefore, 10 μg/mL APH was used in 
subsequent experiments.  
To confirm that APH treatment could inhibit DNA replication, I treated M059K 
cells with 10 μg/mL APH for 24 h, added BrdU to the media, and then examined the 
incorporation of BrdU by immunofluorescence microscopy (Figure 18). In the absence of 
APH, 30% ± 1% of cells incorporated BrdU in their nuclei whereas only 5% ± 1%  of 
APH-treated cells had BrdU in their nuclei (t = 6.31; d.f. = 1; p < 0.05) confirming that 
DNA replication was inhibited. Treatment with APH also reduced asynchronous BrdU 
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incorporation in micronuclei from 17% ± 4% in non-treated cells to 4% ± 1% (t = 6.31; 
d.f. = 1; p < 0.05). These data confirmed that that BrdU incorporation is dependent upon 
DNA replication and that blocking replication prevents BrdU incorporation in both the 
main nuclei and micronuclei of M059K cells.  
By characterizing several of the parameters of micronuclei formation and by 
validating methods to study micronuclei using inhibitors, I could now test the relationship 
between DNA replication and damaged DNA in micronuclei. I tested if inhibiting DNA 
replication by APH treatment would change histone γH2AX levels within micronuclei. 
Cells were either non-treated or treated with 10 μg/mL APH and then stained with 
histone γH2AX antibodies, and observed by immunofluorescence microscopy (Figure 
19). The percentage of micronuclei that were positive for histone γH2AX was 54% ± 5% 
in non-treated cells and was reduced to 32% ± 10% (t = 6.31; d.f. = 1; p < 0.05) in APH-
treated cells. These data indicated that DNA replication has a role in damaging DNA in 
micronuclei. Therefore, micronuclei can acquire damage in the absence of a genotoxic 
treatment. 
I then explored the effects of a genotoxic treatment upon histone γH2AX signals 
in micronuclei in M059K cells. Cells were either non-treated, treated with 30 μM 
cisplatin for 48 h, or with 30 μM cisplatin for 24 h and then co-treated APH for an 
additional 24 h. Cells were then stained with DAPI and anti-histone γH2AX antibodies 
and observed by immunofluorescence microscopy (Figure 19B and C). I observed that 
83% ± 6% of micronuclei contained histone γH2AX signals in the presence of cisplatin. 
By contrast, only 67% ± 8% of micronuclei had histone γH2AX signals in cells co-
treated with cisplatin and APH (t = 2.92; d.f. = 2; p < 0.05). Under these conditions, the 
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percentage of cells with micronuclei after treatment with APH and cisplatin was similar 
to that of cells in the non-treated populations (Figure 19C). These data confirmed that 
micronuclei acquire additional damage in the presence of cisplatin and that treatment 
with APH can both limit damage to DNA by cisplatin and prevent cells from forming 
new micronuclei.  
 
4.7. WI-38 cells treated with cisplatin do not form additional micronuclei 
I established a model system using M059K cells in which I could study 
micronuclei in cells that undergo checkpoint adaptation in response to cisplatin treatment. 
During our investigation I observed that micronuclei acquired damaged DNA as a result 
of aberrant DNA replication. With this information, I was now ready to examine if WI-38 
cells, which are not cancerous, undergo a similar response to cisplatin as observed in 
M059K cells. 
I observed that new micronuclei arise in M059K cells treated with cisplatin, but 
these are cancer cells and known to have impairments to the DNA damage checkpoint 
and DNA repair pathways [143-145]. Since WI-38 cells are normal cells and have 
functional DNA damage checkpoints and repair pathways, I predicted that additional 
micronuclei would not form following genotoxic treatment [126]. To test this prediction, 
I treated WI-38 cells with 30 μM cisplatin for up to 120 h. Cells were stained with DAPI 
and then observed by immunofluorescence microscopy (Figure 20). During the first 48 h, 
no morphological changes were observed in cells treated with 30 μM cisplatin. However 
after 72 h, I observed cells undergoing apoptotic cell death as they displayed discrete, 
brightly-stained chromatin structure [68, 119, 122, 128]. Between 96 and 120 h the 
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number of apoptotic cells increased, as well as material from dead cells. The highest 
percentage of micronucleated cells observed was 5% ± 2% at 96 h but this was not 
statistically significant (p > 0.05). In addition, I did not detect cells with NPBs. These 
data suggested that cisplatin does not induce micronuclei formation in WI-38 cells but 
rather causes apoptotic cell death.  
 
4.8. WI-38 cells do not undergo checkpoint adaptation at a detectable frequency 
Since micronuclei were not observed in WI-38 cells treated with cisplatin, I 
predicted that these cells do not undergo checkpoint adaptation. To address this, I 
examined cells for the steps of checkpoint adaptation. First, I examined WI-38 cells 
treated with cisplatin for levels of histone γH2AX. Cells were either non-treated or 
treated with different concentrations of cisplatin (10-300 μM) for 48 h, stained with 
DAPI and anti-histone γH2AX antibodies, and then observed by immunofluorescence 
microscopy (Figure 21). The results were similar to those of M059K cells; the percentage 
of WI-38 cells positive for histone γH2AX after treatment with 30 μM cisplatin was 79% 
± 3%, but it significantly increased to 95% with treatments of 100 μM or greater (t = 
6.31; d.f. = 1; p < 0.05). At concentrations lower than or equal to 30 μM, most cells had 
histone γH2AX foci but at concentrations greater than 30 μM cisplatin, pan-nuclear 
staining was observed. The presence of histone γH2AX pan-nuclear staining indicates 
that these cells have acquired more damage than those with histone γH2AX foci. Non-
treated WI-38 cells did not stain for histone γH2AX. Nearly all WI-38 cells died after 
treatment with greater than 100 μM cisplatin; therefore it was not possible to study 
micronuclei formation in survival cells, as I did with M059K cells. These data revealed 
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that although the DNA of WI-38 cells can be damaged by cisplatin treatment, only a very 
small percentage of cells form micronuclei. 
To better understand the differences in the production of micronuclei that I 
observed between WI-38 and M059K cells, I investigated the response by WI-38 to 
cisplatin and corresponding damaged DNA.  I tested if cisplatin induced the activation of 
the DNA damage checkpoint in WI-38 cells. I prepared protein extracts from cells that 
were either non-treated or treated with cisplatin for 24 h and examined them for phospho-
Ser345-Chk1, via western blotting (Figure 22A). Similarly to M059K cells, phospho-
Ser345-Chk1 was present in cisplatin treated cells but absent in non-treated cells. 
Comparison of total Chk1 levels revealed the difference in the phosphorylation was also 
accompanied with an increase in Chk1 levels. Actin levels showed equal loading of 
protein extracts. These data support that WI-38 cells initiate the DNA damage checkpoint 
by activating Chk1 after treatment with 30 μM cisplatin.  
I tested if WI-38 cells underwent a cell cycle arrest after treatment with cisplatin. 
Cells were non-treated, treated with 200 ng/mL of nocodazole (G2/M-phase control), or 
treated with 30 μM cisplatin, and then analyzed at 24 h by flow cytometry (Figure 22B 
and C). Non-treated cells were predominantly in the G1/G0-phase with the remaining 
cells in either the S-phase or G2/M-phase. Cells treated with nocodazole accumulated in 
the G2/M-phase. In contrast to M059K cells (Figure 11), there were no differences in the 
percentages of WI-38 cells in S-phase or G2/M-phase after treatment with cisplatin 
compared to non-treated cells.  
I then examined if cisplatin treated WI-38 cells express cyclin B1, which is 
required for mitosis.  Cells were either non-treated or treated with 30 μM cisplatin for 48 
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h and then stained with anti-cyclin B1 antibodies and observed by immunofluorescence 
microscopy (Figure 23). I observed that 13% ± 1% of non-treated cells and 22% ± 1% of 
cells treated with 30 μM cisplatin for 48 h were positive for cyclin B1 (t = 6.31; d.f. = 1; 
p < 0.05). These data confirm that the majority of WI-38 cells were not “primed” to enter 
mitosis although most had damaged DNA, which was consistent with the lack of 
micronuclei observed during cisplatin treatments. 
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Figure 1. An overview of the DNA damage checkpoints. In the presence of damaged 
DNA the ataxia telangiectasia mutated (ATM)/ATM and Rad3-related (ATR) kinases are 
activated and initiate a phosphorylation cascade. This causes cells to arrest in either G1/S 
(left) or G2/M phase (right) of the cell cycle through inhibition of cyclin dependent 
kinases (Cdks). Bold lines indicate active proteins whereas dotted lines show inactive 
proteins. Phosphorylation events are marked by the letter P. 
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Table 1. Description of genotoxic agents, their mechanism of action, and the type of 
DNA damage they induce [19]. 
 
  
Genotoxic agent
Chemical
structure
Mechanism of action
Type of DNA
damage
Pharmacological
treatment range
Camptothecin
(CPT)
Topoisomerase I inhibitor.
Prevents religation of
DNA nicks.
DSB and
SSB
2.8 nM to 17.3
nM
S23906 -1
Binds to N2 of guanine in
minor DNA groove.
Induces
intra -stranded, and inter -
stranded DNA cross-links.
DSB and
SSB
1 µM to 10 µM
cis-
diamminedichloro
platinum
(Cisplatin )
Binds to N7 guanine and
adenine. Induces
intra -strand, inter-strand,
and DNA-protein
crosslinks.
DSB, SSB,
and AP sites
12 µM to 40 µM
N
N
O
O
OOH
N O
O
O O
O
O
O
Pt
NH3
+
NH3
+
Cl
Cl
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Figure 2. Overview of micronuclei formation in cells with damaged DNA. Cells with 
damaged DNA can enter mitosis. Lagging whole chromosomes or acentric chromosome 
fragments (top), which do not properly attach to the spindle apparatus, are not 
incorporated into daughter nuclei and instead form micronuclei. Damaged chromosomes 
may also fuse to form a dicentric chromosome (bottom), which is pulled to opposite poles 
during anaphase. This creates a nucleoplasmic bridge (NPB) between daughter nuclei, 
which then breaks after cytokinesis. DNA fragments from broken NPB are enclosed by 
micronuclei. 
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Figure 3. Overview for the steps required for checkpoint adaptation after treatment with a 
genotoxic agent [3]. Proliferating cells arrest in the cell cycle after detection of damaged 
DNA. Cells then enter mitosis with damaged DNA. Most cells die in mitosis; however a 
small number survive and are predicted to have a rearranged genome. 
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Figure 4. Human glioma fibroblasts contain micronuclei and nucleoplasmic bridges. 
M059K cells were stained for either DNA (left) or lamin A/C (right) and observed by 
immunofluorescence microscopy. Arrows indicate a micronucleus (top) or a 
nucleoplasmic bridge (bottom). Scale bar = 25 µm.  Images are representative of two 
experiments. 
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Figure 5. Normal human lung fibroblasts are unlikely to have micronuclei. WI-38 cells 
were stained for DNA (left) or lamin A/C (right) and observed by immunofluorescence 
microscropy. The nuclei of three cells are shown. Arrows indicate a micronucleus. Scale 
bar = 25 µm. Images are representative of two experiments. 
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Figure 6. Cells treated with different concentrations of genotoxic agents have reduced 
cell viability. M059K and WI-38 cells were treated with different concentrations of either 
camptothecin (CPT) (A and B), S23906-1 (C and D), or cisplatin (E and F) for 48 h 
(squares), 96 h (diamonds), and 120 h (circles). Cell viability was measured by the MTT 
assay. Means of three experiments and standard error of means is shown. 
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Table 2.  Mean IC50 concentrations of different genotoxic agents used to treat either 
M059K or WI-38 cells for 48 and 96 h. 
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Figure 7. Treatment with cisplatin increases the percentage of micronucleated M059K 
cells and micronuclei per cell, over time (h). Cells were treated with 30 μM cisplatin for 
up to 120 h. At least 200 cells were counted and experiments were repeated five times. 
A. Cells were fixed at indicated times, stained for DNA, and observed by 
immunofluorescence microscopy. Scale bar equals 25 μm. 
B. Mean percentage of micronucleated cells and standard error of means is shown. 
Asterisks show significant difference. t(4) = 2.13, p < 0.05. 
C. Mean percentage of micronuclei per cell and standard error of means is shown. 
Asterisks show significant difference. t(4) = 2.13, p < 0.05. 
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Figure 8. Increasing concentrations of cisplatin increase the percentage of micronuclei in 
M059K cells. Cells were treated with the indicated concentrations of cisplatin for 48 h. 
At least 200 cells were counted and experiments were repeated twice. The mean 
percentage of cells with micronuclei was calculated at each concentration. Standard error 
of means is shown. Asterisks show significant differences. t(1) = 6.31, p< 0.05. 
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Figure 9. M059K cells retain micronuclei 8-10 days after treatment with cisplatin. 
A. Cells were either non-treated (left) or treated with 30 µM cisplatin (right) for 120 h 
and then cultured for 8-10 days. Cells were stained to mark DNA and then observed by 
immunofluorescence microscopy. Arrows indicate the presence of a micronucleus. Scale 
bar equals 25 µm. At least 200 cells were counted and experiments were repeated at least 
three times. 
B. The mean percentage of micronucleated cells was calculated. Standard error of means 
is shown. Asterisk shows significant difference. t(5) = 2.01, p < 0.05. 
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Figure 10. Cells signal damaged DNA in a dose-dependent manner following treatment 
with cisplatin. At least 200 cells were counted and experiments were repeated twice. 
A. M059K cells were treated with increasing concentrations of cisplatin for 48 h and then 
stained for either DNA (top) or histone γH2AX (bottom). Cells were observed by 
immunofluorescence microscopy. Scale bar equals 50 µm. 
B. The mean percentage of cells positive for histone γH2AX. Standard error of means is 
shown. Asterisks show significant differences. t(1) = 6.31, p < 0.05. 
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Figure 11. M059K cells engage the DNA damage checkpoint in response to treatment 
with cisplatin. Experiments were repeated at least twice. 
A. Protein extracts were prepared from cells that were either non-treated or treated with 
30 µM cisplatin for 24 h. Samples were processed by western blotting and antibodies 
against phospho-Ser345-Chk1, Chk1, or actin. 
B. Cells were non-treated (NT), treated with 200 ng/mL nocodazole (Noco.), or 30 µM 
cisplatin for 24 h and then analysed by flow cytometry. DNA content was determined 
with propidium iodine staining. 
C. Mean percentage of cells in each phase of the cell cycle. 
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Figure 12. M059K cells treated with cisplatin accumulate cyclin B1 after 48 h. Cells were 
either non-treated or treated with 30 μM cisplatin for 48 h. At least 200 cells were 
counted and experiments were repeated twice. 
A. Cells were stained for either DNA (top) or cyclin B1 protein (middle) and then 
observed by immunofluorescence microscopy. Merge of images is shown on bottom. 
Scale bar equals 50 μm. 
B. The mean percentage of cells positive for cyclin B1 was calculated. Standard error of 
the means is shown. Asterisk shows signifcant difference. t(1) = 6.31, p < 0.05. 
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Figure 13. Inhibition of Chk1 increases the percentage of micronucleated M059K cells. 
Cells were non-treated, treated with 15 nM Gö6976 for 24 h, 30 μM cisplatin for 48 h, or 
30 μM cisplatin for 24 h and then co-treated with 15 nM Gö6976 for an additional 24h. 
At least 200 cells were counted and experiments were repeated three times. 
A. Cells were stained for DNA and then analysed by immunofluorescence microscopy. 
Scale bar equals 50 μm. 
B. The mean percentage of micronucleated cells was calculated for each treatment and 
standard error of the means is shown. Asterisks show significant differences. t(2) = 2.92, 
p < 0.05. 
  
0
10
20
30
40
50
NT Gö6976 Cisplatin Cisplatin +
Gö6976
%
of
m
ic
ro
nu
cl
ea
te
d
ce
lls
NT Gö6976 Cisplatin Gö6976 + CisplatinA
B * * *
72 
 
 
Figure 14. Co-treatment with cisplatin and a Cdk1 inhibitor (CR8) prevents new 
micronuclei from forming in M059K cells. Cells were non-treated, treated with 30 μM 
cisplatin, or co-treated with cisplatin and 500 nM CR8 for the indicated times. At least 
200 cells were counted and experiments were repeated three times. 
A. Cells co-treated with cisplatin and CR8 were fixed at the indicated times, stained for 
DNA, and observed by immunofluorescence microscopy. Scale bar equals 25 μm. 
B. The mean percentage of micronucleated cells and standard error of the means is 
shown. Asterisks show significant differences. t(2) = 2.92, p < 0.05. 
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Figure 15. Micronucleated M059K cells show evidence of asynchronous DNA 
replication. Cells were treated with 30 μM BrdU reagent for 30 min. Experiments were 
repeated twice. 
A. Cells were stained for both DNA (left) and BrdU (middle) and then observed by 
immunofluorescence microscopy. Merge of images is shown on right. Scale bar equals 50 
μm. Images are representative of three experiments. 
B. Micronucleated cell stained for DNA (left) and anti-BrdU (middle). Merge of images 
is shown on right. Scale bar equals 25 μm.  
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Table 3. Mean percentage of micronuclei that are incorporating BrdU in relation to the 
main nucleus. Standard error of the means is shown. At least 200 cells were counted and 
experiments were repeated twice. 
  
BrdU
Status % of micronucleated cells
Synchronous 80 ± 7
Asynchronous 20 ± 7
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Figure 16. Micronuclei have damaged DNA. 
M059K cells were stained for both DNA (left) and histone γH2AX (middle) and then 
observed by immunofluorescence microscopy. Merge of images is shown on the right. 
Scale bar equals 25 μm. Images are representative of three experiments. 
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Table 4. Mean percentage of micronuclei with damaged DNA. Standard error of the 
means is shown. At least 200 cells were counted and experiments were repeated twice. 
  
Histone γH2AX
Status % of micronuclei
 Positive 47 ± 9
Negative 53 ± 9
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Figure 17. M059K cells treated with aphidicolin accumulate in G1/G0-phase. M059K 
cells were either non-treated, treated with 200 ng/mL nocodazole or with the indicated 
aphidicolin (APH) concentrations for 24 h. Experiments were repeated twice. 
A. Samples were analysed by flow cytometry for DNA content. DNA content was 
determined by propidium iodine staining. 
B. The mean percentage of cells in each phase following indicated treatments is shown. 
Experiments were performed twice.  
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Figure 18. DNA replication is blocked in cells treated with aphidicolin. Cells were either 
non-treated or treated with 10 μg/mL of aphidicolin. At least 200 cells were counted, and 
experiments were repeated twice. 
A. Cells were treated with 30 μM BrdU for 30 min, stained for either DNA (left) or BrdU 
(middle), and then observed by immunofluorescence microscopy. Merge of images is 
shown on the right. Scale bar equals 50 μm. 
B. Mean percentage of cells undergoing replication. Standard error of the means is 
shown. Asterisks show significant differences. t(1) = 6.31, p < 0.05. 
C. Mean precentage of micronucleated cells undergoing asynchonous replication. 
Standard error of the means is shown. Asterisks show significant differences. t(1) = 6.31, 
p < 0.05.  
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Figure 19. Treatment with aphidicolin results in fewer micronucleated M059K cells and 
fewer micronuclei that are positive for histone γH2AX. Cells were non-treated, treated 
with 10 μg/mL aphidicolin (APH) for 24 h, 30 μM cisplatin for 48 h, or treated with 
cisplatin for 24 h and then co-treated with APH for an additional 24 h. At least 200 
micronucleated cells were counted and experiments were repeated twice. 
A. Cells were stained for either DNA (left column) or histone γH2AX (middle). Merge of 
images is shown on right column. Cells were observed by immunofluorescence 
microscopy. Scale bar equals 25 μm. 
B. Mean percentage of micronuclei positive for histone γH2AX. Standard error of means 
is shown. Asterisks show significant differences. t(2) = 2.92, p < 0.05. 
C. Mean percentage of micronucleated cells. 
Standard error of means is shown. Asterisks show significant differences. t(2) = 2.92, p < 
0.05.  
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Figure 20. Treatment of WI-38 cells with cisplatin does not increase the percentage of 
micronucleated cells. At least 200 cells were counted and experiments were repeated 
twice. 
A. Cells were treated with 30 μM cisplatin for up to 120 h and then fixed at indicated 
times, stained for DNA, and observed by immunofluorescence microscopy. Scale bar 
equals 25 μm. 
B. The mean percentage of micronucleated cells was determined and compared over 
time. Standard error of means is shown. 
Experiments were repeated twice. 
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Figure 21. WI-38 cells signal damaged DNA in a dose-dependent response following 
treatment with cisplatin. At least 200 cells were counted and experiments were repeated 
twice. 
A. Cells were treated with increasing concentrations of cisplatin for 48 h and then stained 
for either DNA (top) or histone γH2AX (bottom). Cells were observed by 
immunofluoroscence microscopy. Scale bar equals 50 µm. 
B. The mean percentage of cells positive for histone γH2AX was calculated at each 
cisplatin concentration and standard error of means is shown. Asterisks show significant 
differences. t(1) = 6.31, p < 0.05. 
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Figure 22. WI-38 cells activate Chk1 in response to treatment with cisplatin. Experiments 
were repeated twice. 
A. Protein extracts were prepared from cells that were either non-treated or treated with 
30 µM cisplatin for 24 h. Samples were processed by western blotting and antibodies 
against either phospho-Ser345 Chk1, Chk1, or actin. 
B. Cells were either non-treated, treated with 200 ng/mL nocodazole, or 30 µM cisplatin 
for 24 h and then analysed by flow cytometry. DNA content was determined with 
propidium iodine staining. 
C. Mean percentage of cells in each phase of the cell cycle. 
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Figure 23. Cells treated with cisplatin accumulate little cyclin B1 after 48 h. WI-38 cells 
were either non-treated or treated with 30 μM cisplatin for 48 h. At least 200 cells were 
counted and experiments were repeated twice. 
A. Cells were stained for either DNA (top) or cyclin B1 protein (middle) and then 
observed by immunofluorescence microscopy. Merge of images is shown on the bottom 
row. Scale bar equals 50 μm. 
B. The mean percentage of cells positive for cyclin B1 protein was calculated. Standard 
error of means is shown. Asterisk shows significant differences. (1) = 6.31, p < 0.05. 
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Chapter 5 - Discussion 
 
 In 2008, The Cancer Genome Atlas (TCGA) sequenced tumour genomes from 
206 glioblastoma patients and reported that every genome had a different nucleotide 
substitutions, gene amplifications, deletions, and chromosomal rearrangements. In a 
follow-up study, chromosome aneuploidy (abnormal chromosome number), was also 
found in the tumour genomes of another 128 glioblastoma patients [108]. This profound 
genomic diversity within each tumour may be the reason why glioblastoma treatments are 
rarely effective; only 3-5% of patients survive more than three years after treatment with 
radiation and/or chemotherapy [106]. To improve patient outcomes, it is necessary to 
understand how tumour genomes acquire these changes.     
 One type of genomic change that is frequently found in cancer cells, including 
glioblastoma cells, is micronuclei. I investigated the relationship between the formation 
of micronuclei and checkpoint adaptation in glioblastoma cells. Checkpoint adaptation, or 
mitosis with damaged DNA, has been suggested as a mechanism of micronuclei 
formation [19], but it has not been previously investigated. I found that glial cancer cells 
(M059K) acquire additional micronuclei after genotoxic treatment with cisplatin. They 
do so after undergoing checkpoint adaptation. Independently of a genotoxic treatment, 
some micronuclei acquire damaged DNA. The damaged DNA acquired by these 
micronuclei was linked to DNA replication [61]. This result is particularly important 
because it suggests that the formation of a micronucleus leads to a process of further 
continuous genomic change, which may account for the genomic diversity reported in 
glioblastoma genomes. I was unable to detect the formation of micronuclei in normal 
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lung fibroblasts (WI-38) treated with cisplatin. Consistent with this observation, WI-38 
cells treated with cisplatin did not undergo checkpoint adaptation. These findings suggest 
that checkpoint adaptation might have a determinant role in how cells respond to events 
that damage their genome. The results from our investigation provide insights into the 
complex problems of genomic change in cancer cells. 
   
5.1. Percentages of micronuclei and nucleoplasmic bridges vary in human cancer cells   
 To study genomic change, I first needed a reliable cellular model to investigate 
the formation of micronuclei. The high number of micronuclei in M059K cells makes 
them a convenient model because one has sufficient numbers to test observations with 
statistical significance. Other cancer cell lines, such as HT-29 (colon) or U2OS 
(osteosarcoma), which are used in the laboratory, also harbour micronuclei, but only 2-
5% of cells have them. I detected that 25% ± 1% of M059K cells contained at least one 
micronucleus in addition to the main nucleus (Figure 4). Some previous studies have 
reported lower percentages (1-7%) of micronuclei in these cells [116, 125]. However, 
these studies only used one staining method in their counting procedures. I confirmed the 
presence of micronuclei with additional counting methods: lamin A/C, histone γH2AX, 
and BrdU. Lymphocytes isolated from thyroid cancer patients have been reported to have 
similar percentages of cells with micronuclei (27%) [146]. The high percentage of 
micronuclei in M059K cells, and their capacity to undergo checkpoint adaptation [3] 
makes them a convenient model to study the relationship between micronuclei and 
checkpoint adaptation.  
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Consistent with our observations, the American Tissue Cell Culture has reported 
that M059K cells do not contain a stable number of chromosomes [115]. Typically, 
M059K cells have 65 to 79 chromosomes and at least 22% of cells exhibit polyploidy. 
Gurung et al. reported that non-treated M059K cells can have more than 87 chromosomes 
and have several complex chromosomal rearrangements, including reciprocal and non-
reciprocal translocations [114]. An abnormal chromosome number is common in cells 
with micronuclei because micronuclei are often caused by unequal separation of 
chromosomes [61, 71]. Other genomic changes including reciprocal and non-reciprocal 
translocations have been reported to occur to chromosomes inside a micronucleus [61]. 
The presence of micronuclei helps to explain the variation in the number of chromosomes 
and the genomic rearrangements described in these cells. 
 
5.2. Characterization of genotoxic molecules 
 Having selected M059K cells to study micronuclei, I then needed a genotoxic 
agent with which to induce checkpoint adaptation. I required a genotoxic agent that has 
an IC50 concentration to cultured cells that was similar to that used in clinical trials, and a 
difference in cell viability between early (48 h) and late (120 h) times after treatment 
[19]. I found that 30 µM cisplatin met these conditions. By choosing these criteria, I 
maintained a critical link between our experimental results and pharmacological results in 
treated patients [19, 130]. Cisplatin induced a cytotoxic response in both M059K cells 
and WI-38 cells (Figure 6E and F), at a concentration that was within the treatment range 
received by patients (12-40 µM) [19, 134-136]. Concentrations that exceed 40 µM are 
reported to cause liver and kidney failure, hearing loss, pancytopenia (reduction of blood 
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cells), and death in human patients [134] and are therefore not pharmacologically 
relevant. Importantly, 80% of M059K cells and 90% of WI-38 cells that were alive at 48 
h had died after 120 h treatment with 30 µM cisplatin. The delay in the reduced cell 
viability between 48 h and 120 h is typical of cells that undergo checkpoint adaptation 
prior to cell death [3]. If the concentration of cisplatin was too high (100-300 µM), cells 
would die during the first 48 h and if the concentration was too low (0.3-3 µM) cisplatin 
was not effective in reducing cell viability. Therefore, I chose to treat cells with 30 µM 
cisplatin because they exhibited the ideal cytotoxic response to study checkpoint 
adaptation. 
  
5.3. M059K cells treated with cisplatin form micronuclei 
 Having characterized our experimental model, I then tested if M059K cells 
formed new micronuclei or nucleoplasmic bridges (NPBs) following cisplatin treatment 
(Figure 7). I observed three changes in cells: (1) an increase in cells with micronuclei 
over 96 h from 24% ± 1% to 48% ± 7%;  (2) an increase in the number of micronuclei 
per cell with an increase in treatment time; and (3) an increase in NPBs from 1% to 3% 
after 120 h. These observations are consistent with other studies that have reported that 
cisplatin also induces micronuclei formation in cancerous epithelial cells (HeLa and 
HT1080) [68, 147] and skin fibroblast cells [64]. 
 There are conflicting reports on whether micronuclei are retained by cells. Some 
suggest that micronuclei are either degraded or exported out of the cells before the next 
mitosis cycle [63, 78, 148]. Others have reported that micronuclei are stably maintained 
by cells throughout interphase, and are sometimes reincorporated back into the main 
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nucleus in a subsequent mitosis [61]. I observed that 47% of cells still had micronuclei 8 
to 10 days post treatment, which suggests that micronuclei are retained (Figure 8). Our 
findings are consistent with observations made by Crasta et al., who reported that 97% of 
the micronuclei in U2OS cells were maintained throughout interphase, and that 84% of 
micronucleated cells that underwent mitosis gave rise to daughter cells with micronuclei 
[61]. 
 
5.4. Micronuclei arise in M059K cells that undergo checkpoint adaptation 
 Having confirmed that M059K cells treated with cisplatin formed micronuclei, I 
then investigated whether checkpoint adaptation was required for this process since both 
involve mitosis. The relationship between micronuclei and mitosis is well known. Recall 
that micronuclei originate during anaphase from lagging whole chromosomes [61, 62] or 
acentric chromosome fragments [63] that fail to be incorporated into daughter nuclei 
during telophase. This process can occur in mitotic cells that have unrepaired (or 
incorrectly repaired) DNA breaks [64, 65], dysfunctional mitotic spindles complexes or 
microtubules [66-68], defects in kinetochore proteins or assembly [69-71], and/or a 
defective mitotic checkpoint [71].  
 Cisplatin both damages DNA and triggers the synthesis of extra mitotic spindles, 
which can produce lagging chromosomes. Recall that 33% ± 1% of M059K cells 
contained six or more micronuclei after treatment with cisplatin for 120 h (Figure 7C). 
This response is typical of cells that have undergone a multipolar mitosis [67, 68]. 
Maskey et al. reported that HeLa cells treated with cisplatin synthesize additional spindle 
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complexes that then pull chromosomes to more than two poles during anaphase [68]. As 
a result of this process cells formed multiple micronuclei.  
Although a multipolar mitosis can explain how a cell with multiple micronuclei 
formed, it does not account for cells that have only one or two micronuclei. However, if I 
consider that cisplatin treated cells have damaged DNA while in mitosis, I are able to 
better explain how fewer micronuclei arise. Jirsova et al. reported that DNA breaks 
induced by cisplatin caused chromosome segregation errors in mitosis and gave rise to 
micronuclei that contained chromosome fragments in skin fibroblasts [64]. Damaged 
DNA induced by cisplatin is also reported to trigger mitotic death in HT1080  cells [68] 
and ovarian cells (SKOV-3) [149]. These findings confirmed that cells treated with 
cisplatin can enter mitosis with damaged DNA. 
One pathway that allows entry into mitosis with damaged DNA is checkpoint 
adaptation. Checkpoint adaptation is characterized by three steps: (1) DNA damaged 
induces cell cycle arrest in G2-phase; (2) overcoming this arrest; (3) and entry into 
mitosis with damaged DNA [87]. Two key enzymes required for this process are Chk1 
and Cdk1, which upon activation, control the arrest in G2-phase and entry into mitosis 
respectively [3]. Checkpoint adaptation has been previously observed in M059K cells 
treated with CPT [3], however, its relationship to genomic change and micronuclei had 
yet to be investigated. 
  In our experiments, M059K cells treated with cisplatin demonstrated the key 
steps of cells preparing to undergo checkpoint adaptation: they signalled DNA damage by 
histone γH2AX (Figure 10), they activated Chk1 (Figure 11), they arrested in S-phase 
and G2/M-phase, and the majority of cells expressed cyclin B1 (Figure 12). With this 
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information I could then modify the key enzymes that control checkpoint adaptation by 
the use of chemical inhibitors, and examine the effects upon micronuclei formation.  
 If checkpoint adaptation and micronuclei were linked, I would predict that the 
inhibition of Chk1 would cause more cells to enter mitosis with damaged DNA and 
generate additional micronuclei. I tested if M059K cells with damaged DNA would form 
more micronuclei in the presence of the Chk1 inhibitor Gö6976 [140]. I observed that the 
percentage of micronuclei in cells co-treated with Gö6976 and cisplatin was 37% ± 3% 
(Figure 13). By comparison, the percentage of cells with micronuclei after treatment with 
cisplatin alone was 27% ± 1%. This finding suggested that when Chk1 is active, cells do 
not enter mitosis with damaged DNA and thus do not form micronuclei. Our observations 
are consistent with those of Petsalaki et al. who reported that Chk1-deficient human 
colon carcinoma cells (BE) form additional micronuclei and NPBs after treatment with 
etoposide [150]. Our results are also consistent with those of Bartkova et al. who reported 
that when the DNA damage checkpoints are active, including Chk1, tumour growth is 
suppressed, but when the DNA damage checkpoints are inhibited, cell proliferation 
occurs and tumour size increases [151]. 
 I predicted that inhibiting Cdk1 would prevent cells with damaged DNA from 
entering into mitosis and thus stop the formation of new micronuclei. I then tested if 
M059K cells with damaged DNA formed new micronuclei in the presence of the Cdk1 
inhibitor CR8 [13].  CR8 is an ATP competitor that blocks the active site of Cdk1 and 
related Cdks [12, 13]. CR8 has been shown to block mitosis in HT-29 cells, thereby 
preventing checkpoint adaptation [3, 10]. I co-treated cells with CR8 and cisplatin 
(Figure 14) and observed that the proportion of micronucleated cells did not change 
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compared to non-treated cells. Our findings are consistent with those of Kubara et al. 
who reported that in the presence of CR8, HT-29 cells that have damaged DNA do not 
undergo mitosis as measured by cell rounding and the phosphorylation of histone H3 on 
serine 10 [3]. I now provide evidence that CR8 also stops the formation of micronuclei by 
preventing checkpoint adaptation.    
 
5.5. Micronuclei cause additional damage to DNA 
 While studying the relationship between micronuclei and checkpoint adaptation, I 
observed that nearly half of the micronuclei had damaged DNA in the absence of 
genotoxic treatment. Crasta et al. reported that the DNA in a micronucleus undergoes 
aberrant DNA replication which damages DNA in two steps [61]. First, DNA breaks are 
introduced during DNA replication but are not repaired. Second, DNA replication often 
occurs in late G2-phase and if not completed prior to mitosis, chromosomes prematurely 
condense and fragment into several pieces. Importantly, micronuclei that undergo this 
process can be identified by the presence of damaged DNA and by DNA replication that 
occurs asynchronously to the main nucleus.  
 In our experiments, the micronuclei in M059K cells demonstrated several signs of 
aberrant DNA replication: 20% ± 7% signalled that they were undergoing asynchronous 
DNA replication (Figure 15; Table 3) as measured by the incorporation of the thymidine 
analogue, 5-bromo-2’-deoxyuridine (BrdU) and 47% ± 9% signalled damaged DNA by 
histone γH2AX (Figure 16; Table 4). Our observations are consistent with those of Crasta 
et al. who reported that 30% of micronuclei in epithelial cells (RPE-1) have 
asynchronous BrdU signals and 60% of micronuclei have histone γH2AX [61]. With this 
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information I could then inhibit the DNA polymerases required for replication by the use 
of chemical inhibitors, and examine the effects upon histone γH2AX signalling. 
 The results from the histone γH2AX signals suggested that micronuclei acquire 
damaged DNA following asynchronous DNA replication. This observation led me to 
predict that the inhibition of DNA polymerase α would reduce that amount of histone 
γH2AX observed. I tested this prediction by treating M059K cells with aphidicolin 
(APH). APH is a  deoxycytidine triphosphate (dCTP) competitor that blocks the active 
site of DNA polymerase α [152]. It has been shown to inhibit DNA replication in M059K 
cells [153]. I observed that in the presence of APH, histone γH2AX signals declined from 
54% ± 5% to 32% ± 10% (Figure 19). Our findings are consistent with that of Crasta et 
al. who reported that blocking DNA replication with excess thymidine also reduced 
histone γH2AX in the micronuclei of RPE-1 and U2OS cells [61]. This finding is 
particularly important because it suggests that the formation of micronuclei after 
checkpoint adaptation leads to a process of continuous genomic change, which may 
account for the genomic diversity in glioblastomas.  
 
5.6. Micronuclei are rare in normal cells   
 I observed that M059K cells treated with cisplatin undergo checkpoint adaptation 
and form micronuclei, and those micronuclei continue to damage their DNA as a result of 
aberrant DNA replication. I then investigated whether normal cells undergo checkpoint 
adaptation or form micronuclei.  
 To study micronuclei formation in normal cells, I needed a cell line that had a 
similar morphology to M059K cells. Since culturing normal neural cells is difficult, I 
93 
 
instead selected WI-38 cells because they are also fibroblasts. I observed that 2% ± 2% of 
WI-38 cells had micronuclei (Figure 5), which was 12.5 times less than the percentage 
observed in M059K cells. Previous studies have reported similar percentages (1%) of 
micronuclei in WI-38 cells, which confirmed our counting methods [126].  
 Consistent with our observations WI-38 cells are reported to have a stable 
chromosome number consisting of 23 chromosome pairs [126, 154]. Buganim et al. 
analyzed the chromosomes in these cells and reported that there were no visible 
chromosomal translocations [154], which are observed in M059K cells with micronuclei 
[114].   
 
5.7. WI-38 cells do not form new micronuclei 
 Having established that micronuclei were 12 times rarer in WI-38 cells than in 
M059K cells, I then tested if new micronuclei would form following treatment with 
cisplatin, as was observed in M059K cells. I treated cells with cisplatin for 120 h, but did 
not observe significant changes in the percentage of micronuclei (Figure 20). Our 
observations are consistent with those of Fink et al. who reported that micronuclei do not 
form in WI-38 cells after treatment with the genotoxic agent neocarzinostatin [126]. 
Micronuclei also do not form in normal skin fibroblasts (WS1) that are exposed to the 
genotoxic agent hydroxyurea [128]. 
 
5.8. WI-38 cells do not undergo checkpoint adaptation 
 Since I did not observe new micronuclei in WI-38 cells treated with cisplatin, I 
tested whether checkpoint adaptation even occurred in these cells. Previous studies have 
94 
 
reported that normal lymphocytes and skin fibroblasts might undergo checkpoint 
adaptation [94, 155]; however, these studies did not apply an analysis of the three steps 
required for checkpoint adaptation: a DNA damage induced cell cycle arrest in G2-phase, 
overcoming this arrest, and resuming mitosis with damaged DNA.  
 In our experiments, WI-38 cells treated with cisplatin signalled damaged DNA by 
histone γH2AX and activated Chk1 protein as was observed in M059K cells, but they did 
not arrest in G2-phase and most did not have cyclin B1. These data suggested that WI-38 
cells may not be capable of undergoing checkpoint adaptation, which may explain why 
there was not an increase in cells with micronuclei.   
 
5.9. Defects in DNA repair and cell-cycle checkpoint proteins may promote checkpoint 
adaptation 
WI-38 cells responded differently to cisplatin compared to M059K cells. M059K 
cells treated with cisplatin undergo checkpoint adaptation and then form new 
micronuclei. By contrast, I could not detect checkpoint adaptation or new micronuclei in 
WI-38 cells. The reasons why checkpoint adaptation did not occur in WI-38 cells are not 
known. I do know that cancer cell lines are typically deficient in one or more of the 
proteins associated with either cycle checkpoints or DNA repair [19].  These deficiencies, 
which are not present in normal cells, may allow cancer cells to undergo checkpoint 
adaptation and form micronuclei in response to genotoxic treatment.  
Interestingly, depletion of either 53PB or Ku70, which are proteins involved in 
double-strand break repair, have been reported to induce micronuclei formation in WI-38 
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cells treated with neocarzinostatin [126]. It is possible that these same deletions may be 
one way to allow checkpoint adaptation to occur in these cells. 
Alternatively, checkpoint adaptation may occur in WI-38 cells if tumour 
suppressor p53 is depleted. p53 has roles in initiating the G1/S DNA damage checkpoint, 
triggering cell death through apoptosis, and signalling repair of double-stranded DNA 
breaks [17, 27-29]. In at least 80% of cancer cell lines, p53 is reported to be non-
functional [17]. M059K cells have a mutated non-functional version of p53 [143, 145, 
156], whereas WI-38 cells have a functional protein p53 [126]. Fink et al. reported that 
the depletion of p53 in WI-38 cells increased the percentage of micronuclei in cells by at 
least six fold [126]. Depletion of p53 is also reported to be necessary for the formation of 
micronuclei in other normal cells (RPE-1 and WS1) [61, 128] with damaged DNA. It is 
therefore possible that the loss of p53 may be another way to induce checkpoint 
adaptation in WI-38 cells prior to the formation of micronuclei. 
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Chapter 6 - Thesis conclusions 
 The purpose of this thesis was to test if there was a relationship between genomic 
change and checkpoint adaptation. I observed that M059K cells treated with cisplatin can 
acquire genomic change in a two-step process. First, cells with damaged DNA enter 
mitosis (checkpoint adaptation) and then produce daughter cells with micronuclei. If cells 
were prevented from entering mitosis with damaged DNA, as was observed by treatment 
with the Cdk1 inhibitor CR8, micronuclei do not form.  By contrast to CR8 treatment, if 
cells were forced to enter mitosis with damaged DNA by treatment with the Chk1 
inhibitor Gö6976, additional micronuclei formed.  
Then I found that once micronuclei are formed, some of them are prone to 
additional DNA damage because they undergo aberrant DNA replication. In addition, 
micronuclei that form in cells are not degraded and/or lost during the cell cycle, which 
means there is potential for continuous genomic change. WI-38 cells, which are not 
cancerous, did not undergo checkpoint adaptation and did not form micronuclei. Since 
normal cells did not enter mitosis with damaged DNA they likely have mechanisms that 
protect them from acquiring genomic change.  
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